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ABSTRACT 
 
 
The Effect of Dietary Polyunsaturated Fatty Acids on Colorectal Cancer and the Development of  
 
the Total Western Diet-2 
  
 
by 
 
 
Sara Kellen, Master of Science 
 
Utah State University, 2014 
 
 
Major Professor: Dr. Korry Hintze 
Department: Nutrition, Dietetics, and Food Science 
 
 
 The Western diet is characterized by the consumption of foods high in omega-6 (n-6) 
fatty acids, leading to high ratios of omega-6 to omega-3 (n-3) fatty acids.  This dietary pattern 
has been hypothesized to cause higher incidences of colorectal cancer (CRC) due to the pro-
inflammatory nature of n-6 fatty acids.  Using an azoxymethane and dextran sodium sulfate 
(AOM+DSS) induced inflammatory model, mice were fed identical diets, varying only in dietary 
polyunsaturated fatty acid (PUFA) concentration and n-6:n-3 ratio.  They included 1.) AIN-93G, 
control diet, containing 7% (kcal) dietary PUFA 7:1 n-6:n-3 ratio, 2.) 2.5% dietary PUFA 1:1 n-
6:n-3 ratio, 3.) 2.5% PUFA 20:1 n-6:n-3, 4.) 10% PUFA 1:1 n-6:n-3, and 5.) 10% PUFA 20:1 n-
6:n-3.  Mice fed the AIN-93G and the 2.5% PUFA with a 1:1 n-6:n-3 ratio resulted in 
significantly higher colon tumor multiplicity (p-value < 0.0001) compared to the other treatments.  
Additionally the ratio n-6:n-3 had a significant effect on tumor size.   Mice fed diets with a PUFA 
ratio of 1:1 had significantly larger tumors than mice fed diets with a PUFA ratio of 20:1. Using 
colon length as a measure of inflammation, no significant differences were found between diet 
treatments. Results from our study suggest dietary PUFA profile influences the etiology of CRC.  
 Rodents are commonly used as pre-clinical animal models to study various human 
diseases.  Typically, mice are fed a purified diet formulated to optimize the animal’s growth and 
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health.  However, these diets are considerably different than the average American diet.  Hintze 
and colleagues developed the Total Western Diet (TWD), which matches both the macro- and 
micronutrient content of the average American diet, giving researchers a rodent diet more suitable 
for studying colon health and related diseases.   The TWD-2 was designed to improve upon the 
TWD by incorporating the complex dietary components of whole-foods known to impact gut 
health.  The TWD-2 is currently the only whole-food-based rodent diet that emulates both the 
macro- and micronutrients of the average American diet.  Initiating studies using the TWD-2, in 
place of the AIN diets, will hopefully make the rodent a better model for human colorectal cancer 
research. 
(77 pages) 
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PUBLIC ABSTRACT 
 
 
The Effect of Dietary Polyunsaturated Fatty Acids on Colorectal Cancer and the Development of  
 
the Total Western Diet-2 
 
by 
 
Sara Kellen 
 
 The Western diet is commonly consumed by industrialized societies and characterized by 
an increased consumption of vegetable oils rich in omega-6 (n-6) fatty acids. This results in a 
higher ratio of omega-6 to omega-3 (n-3) fatty acids in the diet.  Omega-6 polyunsaturated fatty 
acids (PUFA) are believed to induce a pro-inflammatory response in the body.  Therefore, this 
change in PUFA concentration and/or ratio of n-6:n-3 in the Western diet may contribute to 
colorectal cancer (CRC) risk.   Five identical diets, varying only in PUFA concentration and n-
6:n-3 ratio, were fed to mice dosed with a carcinogen and an inflammatory accent (AOM+DSS).  
The diets included: 1.) AIN-93G, control diet, containing 7% (kcal) dietary PUFA, 7:1 n-6:n-3 
ratio, 2.) 2.5% dietary PUFA 1:1 n-6:n-3 ratio, 3.) 2.5% PUFA 20:1 n-6:n-3, 4.) 10% PUFA 1:1 
n-6:n-3, and 5.) 10% PUFA 20:1 n-6:n-3.  PUFA ratio had a significant effect on tumor size. 
Diets having an n-6:n-3 ratio of 1:1 resulted in significantly larger tumors than diets with an n-
6:n-3ratio of 20:1.  Mice fed either the AIN-93G or 2.5% 1:1 diet had the highest number of 
tumors compared to the other experimental diets.  From these results, it appears that the dietary 
PUFA profile influences the etiology of CRC. 
 Studies investigating CRC commonly use rodent models to investigate human diseases.  
Typically rodents are fed diets formulated to promote growth and heath, however these diets are 
considerably different than the Western diet in terms of macro- and micronutrients.  Diet is 
known to influence CRC incidence, which led to the development of the Total Western Diet 
(TWD) by Hinze and colleagues. The TWD is a rodent diet that uses purified ingredients to 
match the macro- and micronutrient composition of the average American diet.  However, the 
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complex nature of whole-foods is also known to impact colon health, so the TWD was 
redesigned.  The TWD-2 is the only whole-foods-based rodent diet that emulates the macro- and 
micronutrient consumption of the average American.  Initiating studies using the TWD-2, in 
place of the AIN diets, will hopefully make the rodent a better model for human disease research. 
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 CHAPTER 1 
INTRODUCTION 
 
 
The Western Diet 
 
Dietary patterns have changed significantly since the Palaeolithic era, when human 
consumption patterns were characterized by an overall low caloric intake and diets were largely 
composed of lean meats, leafy green vegetables, nuts, and fruits (1). Today, in many developed 
industrialized societies, the Western diet is commonly consumed. The Western diet is 
characterized by an overall increase in energy intake, with a large portion of daily calories 
coming from processed meats, refined grains, and sweets. This eating pattern has been 
correlated to a number of health issues from metabolic syndrome to colon cancer (2-4).  
Immigrants who adopt the Western diet typically acquire the disease risks associated with this 
dietary pattern, which are often uncommon in their native culture (2). This skewed consumption 
pattern of the Western diet results in an increased overall intake of omega-6 fatty acids, due to 
increasedconsumption of vegetable oils, creating a higher ratio of omega-6 (n-6) to omega-3 (n-
3) fattyacids in the diet (5). During the Palaeolithic era the ratio of n-6 to n-3 fatty acids was 
approximately 1:1, but current dietary patterns of the Western diet have resulted in a 
significantly unbalanced ratio of n-6 to n-3, and is estimated to be as high as 20-30:1 in some 
populations (5). This increase in n-6 consumption may be attributed to dietary recommendations 
that suggest to replace saturated fatty acids with polyunsaturated fats to lower total and LDL 
cholesterol levels (6, 7).  Along with these dietary recommendations was the development of 
new food processing technologies that made large-scale production of vegetable oils more 
efficient and economical.  This increase in n-6-rich vegetable oil production and the subsequent 
dietary recommendations are recognized as key factors responsible for the increase in n-6 
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polyunsaturated fatty acid (PUFA) intake in the Western diet (6, 7). 
 
PUFA and Gut Inflammation 
 Omega-6 and omega-3 fatty acids consumed in the diet can be converted into signaling 
molecules in the body that have either a pro-inflammatory or an anti-inflammatory effect, 
respectively (8). Therefore, it is not surprising that increased levels of n-6 fatty acids have been 
shown to promote inflammatory diseases like Crohn’s disease and ulcerative colitis (7, 9).  
Crohn’s disease (CD) and ulcerative colitis (UC) are commonly classified under the more 
comprehensive term, inflammatory bowel disease (IBD). The cause of IBD is not well 
understood, but immunologic abnormalities, genetic predisposition, and environmental factors are 
all believed to contribute to the etiology of these diseases (10). These gut inflammatory diseases 
have been consistently associated with the etiology of colon cancer. The risk for colorectal cancer 
is believed to increase the longer IBD goes untreated (11, 12). The chronic inflammation 
associated with these diseases is thought to induce DNA modifications resulting in abnormal cell 
growth and an environment favorable for tumor development (13).  Not surprisingly, the 
significant imbalance of the n-6 to n-3 ratio present in the Western diet is believed to influence 
the prevalence of CRC in Western societies.  In a large cohort study, researchers found that rates 
of CRC were higher in women consuming a Western type diet (3). 
 
Colorectal Cancer (CRC) 
 CRC is the third leading cause of cancer-related fatalities in the United States and is 
projected to cause over 50,000 deaths in 2014 (14). This disease primarily affects Caucasians, 
African Americans, and individuals over the age of 50 (14). Incidence rates of colorectal cancer 
are not uniform throughout the world. Most cases are localized in North America, Australia, New 
Zealand, and parts of Europe, indicating environmental factors greatly influence disease 
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prevalence.   Epidemiological studies have recognized dietary habits and a sedentary lifestyle as 
the major environmental factors attributing to the increased risk of CRC (15).  Along with 
environment factors and chronic gut inflammatory diseases, genetically inherited syndromes like 
familial adenomatous polyposis (FAP) and hereditary nonpolyposis colorectal cancer pose a 
significant threat for CRC occurrence. For insistence, several mutations identified in the tumor 
suppressor gene, adenomatosis polyposis coli (APC) have been shown to lead to the development 
of FAP in individuals.  Researchers have identified a number of other genes shown to induce 
human colon carcinogenesis, including: p53, CTNNB1, IGF12, TGFBR2, KRAS, BRAF, and 
TRP53 (16, 17). 
 
Rodent Colorectal Cancer Models 
 To study colorectal cancer in depth, researchers commonly use rodents as a way to model 
human CRC.  Rodents are relatively inexpensive and they allow scientists to better understand the 
mechanisms of the disease, as well as develop potential treatment options.  In CRC studies, there 
are three common colitis-associated cancer models used today. They include: genetic, xenoplant, 
and chemical models, with each having its own benefits and drawbacks. In the genetic model, 
mice are genetically engineered to have mutations known to cause CRC.  A common genetic 
model used by researchers is a knockout APC mouse. Through the introduction of a number of 
different mutations within the APC gene, tumor development similar to those found in patients 
with FAP will arise (16).  In xenoplant models, tumor cells are subcutaneously or intravenously 
injected into genetically engineered immunodeficient mice, allowing further tumor growth to 
occur in the animal. This type of model, allows researchers to evaluate human tumor growth in 
vivo under different experimental environments (16). Carcinogen-induced colon cancer models 
have shown to be effective methods in creating tumor progression similar to that found in 
humans.   The azoxymethane / dextran sodium sulfate (AOM/DSS) model is frequently used, as it 
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has proven to significantly increase the development of CRC and mimic human disease 
progression (16, 17).  These two compounds work together effectively, as AOM causes tumor 
development and DSS induces inflammation.   AOM is a chemical carcinogen that creates DNA- 
reactive adducts through several metabolic activation steps once in the body.  These DNA 
adducts cause methylation of the nucleic acid guanine, resulting in DNA base pair mismatching. 
DSS is administered orally through drinking water and induces colitis in the animal through its 
cytotoxic effects on the epithelial lining of the colon (16). This CRC model is so effective 
because of how closely the cancer development in the animal resembles CRC development in 
humans (16). 
 
Colon Carcinogenesis 
 Colorectal cancer is caused by a number of cellular dysfunctions and contributing 
environmental factors, which can cause this disease to take years to manifest.  In CRC 
progression, normal epithelial cells lining the gastrointestinal tract will differentiate either 
through genetic predispositions or through environmental factors, leading to dysplasia (16). The 
earliest signs of neoplasia in the colon are dysplastic aberrant crypt foci (ACF). Through 
additional proliferation, ACF’s form microadenomas, which can further evolve into 
macroadenomas and eventually lead to colon cancer (18, 19). In mice treated with AOM + DSS, 
tumors typically arise in the middle and distal portions of the colon creating nodular, polypoid, or 
tubular adenomas/adenocarcinomas, depending on tumor progression (19, 20). 
 
Animal Diets  
 In many rodent models of human disease, animals are commonly fed a purified diet 
formulated by the American Institute of Nutrition (AIN).  AIN developed these diets, AIN-76A 
and AIN-93G, to give scientists a nutritionally adequate diet to help promote growth and fertility 
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of the animal and give scientists a standard to use between research studies (21). However, when 
comparing these formulated diets to the average American diet using nutrient density, they vary 
significantly in both the macro- and micronutrient composition and in dietary complexity. 
Moreover, these diets are formulated with purified ingredients including sugar, cornstarch, casein, 
and soy or corn oil.   Many researchers have proposed other dietary plans to better emulate the 
Western diet, including:  the “cafeteria diet”, the commercialized “Western diet”, and the “New 
Western Diet” (22-24).  While all these diets are more similar to American intakes as compared 
to the AIN diets, they still do not accurately emulate the average American consumption.  The 
only formulated rodent diet that currently matches both the macro- and micronutrient profile of 
Americans is the Total Western Diet (TWD) developed by Hintze and colleagues (4).  To get a 
representation of the typical American diet, data from the National Health and Nutrition 
Examination Survey (NHANES) What We Eat in America for the years 2007-2008 was used (25). 
The average daily intake reported for all nutrients was normalized to calories consumed and 
converted into a nutrient density measurement.  Using a nutrient density approach accounts for 
differences in the metabolic rates between species. 
When comparing the TWD to the AIN diets, significant differences in the macro- and 
micronutrient profiles of these two diets are apparent. The TWD contains fewer calories from 
protein and carbohydrates, and approximately twice the amount from fat (Table 1) (4). The TWD 
also contains approximately half the amount of complex carbohydrates and twice the amount of 
simple sugars compared to the AIN-93G diet. Additionally, the TWD contains only 60% of the 
dietary fiber found in the AIN-93G diet. Another notable difference between these two diets is the 
fatty acid profile. The TWD was designed to include multiple fat sources, thus giving it a more 
diverse fatty acid profile. Fat in the AIN diets comes from either soybean or corn oil, therefore 
resulting in a very simple fatty acid profile, lacking in complexity. A number of notable 
differences also occur in the micronutrient content between these diets (Table 2) (4).  The impact 
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of these discrepancies between the AIN diets and the Western diet have been scrutinized recently 
as a number of studies have shown a correlation between diet, gut microbiome, and colon health 
(26-28).  This connection between diet and gut health suggests a more biologically relevant 
dietary model is needed when investigating the influence of diet on CRC and the microbiome.  To 
date, a whole-food based rodent diet, matching both the macro- and micronutrient levels of 
American consumption, has not been developed. In an effort to explore the impact diet has on gut 
microbiome and subsequent health issues, the Total Western Diet 2 (TWD-2) was formulated. 
 
TABLE 1. Macronutrient composition of the AIN-76A, AIN-93G, and TWD from (4) 
Macronutrient AIN-76Aa AIN-93Ga TWDa 
Carbohydrates 
Corn Starch 150.0 398.0 230.0 
Maltodextrin --- 132.0 70.0 
Sucrose 500.0 100.0 261.0 
Cellulose 50.0 50.0 30.0 
kcal (% of total) 67.7 60.1 54.5 
Proteins 
Casein 200.0 200.0 190.0 
L-cystine --- 3.0 2.85 
DL-methionine 3.0 --- --- 
kcal (% of total) 20.8 18.8 15.4 
Fats 
Soybean Oil --- 70.0 31.4 
Anhydrous Milk Fat --- --- 36.3 
Olive Oil --- --- 28.0 
Lard --- --- 28.0 
Beef Tallow --- --- 24.8 
Corn Oil 50.0 --- 16.5 
Cholesterol --- --- 0.40 
kcal (% of total) 11.5 17.2 34.5 
a Values are g/kg diet for all components  
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TABLE 2. Micronutrient composition of the TWD compared to the AIN-93G from (4) 
Micronutrient AIN-93G TWD 
Minerals (mg/kg diet) 
Calcium 5000.0 2011.0 
Phosphorus 3000.0 2757.0 
Sodium 1019.0 7078.0 
Potassium 3600.0 5333.0 
Magnesium 507.0 589.0 
Iron 35.0 31.0 
Zinc 30.0 25.0 
Copper 6.0 2.6 
Selenium 0.15 0.2 
Vitamins (unit/kg diet) 
Thiamin (mg) 5.0 3.5 
Riboflavin (mg) 6.0 4.4 
Niacin (mg) 30.0 50.6 
Pyridoxine (mg) 6.0 3.9 
Folate (mg) 2.0 1.3 
Vitamin B12 (mg) 25.0 11.0 
Vitamin A (IU) 4000.0 4300.0 
Vitamin D (IU) 1000.0 391.0 
Vitamin E (IU) 75.0 24.6 
Vitamin K (µg)                750.0              189.0 
Choline (mg)               1027.0              648.0 
 
Gut Microbiome and Diet 
 Recently, research involving the role of the gut microbiome on disease incidence has 
made great advances. Emerging evidence suggests that an individual’s gut microbiome greatly 
impacts overall health, playing a role in obesity, colon health, and even immune response (27, 29, 
30).  The types of microbiota found in the gut are believed to influence the development of these 
different health conditions. There are many factors that can affect the diversity of the microbiota 
including age, diet, antibiotic use, and other environmental factors (27).  Recently, diet has been 
identified as a major factor influencing the microbiome, and the microbiota can change rapidly 
with a corresponding change in diet (28).  Bacteria obtain energy through the fermentation of 
dietary components that are not completely digested and absorbed in the upper digestive tract of 
the host (26).  In human diets, undigested carbohydrates that reach the colon can be fermented by 
the gut microbiota to produce short-chain fatty acids (SCFA) and bioactive plant metabolites. 
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SCFAs and plant metabolites have been associated with a decreased risk in cancer.  The bioactive 
plant metabolites are able to turn on endogenous antioxidant genes to help prevent cellular 
damage (31, 32).  The interaction between the metabolites and antigens produced by the gut 
microbiota, along with the metabolites and immune response produced by the host, play a 
significant role in influencing the overall health status of the colon (33). 
 
Metabolomics of the Gastrointestinal Tract 
 Metabolomics is the identification and quantification of metabolites produced in the 
body. These metabolites are produced as a result of the metabolic activity of the host, as well as 
the metabolic activity of the microbes living in the gut. They can be analyzed from a variety of 
sources, such as urine, blood serum, and feces (34).   Analyzing the metabolites present in fecal 
matter allows researchers to identify and quantify metabolites produced from the complex 
interaction between the individual’s metabolic system and their gut microbiome (34, 35).  
Utilizing analytical techniques, such as nuclear magnetic resonance (NMR) or gas 
chromatography-mass spectrometry (GC-MS), allows scientists to categorize and measure 
changes in the metabolomic analytes in response to dietary changes and other environmental 
effects (35).  A large majority of metabolites produced are organic acids, gases, and short chain 
fatty acids (36).  Understanding the effect these metabolites have on the body and how they vary 
in response to dietary changes may help researchers determine the risk for different colon related 
diseases, like CRC. 
 
Effect of Diet on Fatty Acid Profiles  
 Dietary fat plays an essential role in the body by providing a significant source of 
calories, influencing the body’s inflammatory response, and playing a critical role in the 
dynamics of various cellular membranes (37).  Maintaining membrane fluidity is crucial for cells 
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to function properly.  The relative proportion of saturated and unsaturated fatty acids present in 
the membrane aid in the maintenance of this fluidity (37).  Studies have shown dietary fatty acids 
are incorporated into membranes throughout the body in proportions relative to those found in the 
diet. Therefore, changes in dietary fat consumption can lead to shifts in the distribution of fatty 
acids in cell membranes (38-40).  Researchers have examined the distribution of fatty acids in 
response to a number of diseases (38, 40, 41). In a study investigating CRC, the fatty acids in the 
red blood cell (RBC) membranes of CRC and control patients were compared. Researchers found 
CRC patients had significantly higher ratio of n-6:n-3 fatty acids and lower amounts of n-3 fatty 
acids in their RBC membranes.  Researchers believe this difference was caused by an altered lipid 
metabolism in CRC patients (41). 
 
Hypotheses 
PUFA and Colorectal Cancer 
 In response to previous research pertaining to the potential effect of dietary PUFA on gut 
inflammation, a preliminary study by Snow et al. was carried out to investigate the dietary PUFA 
concentration and ratio effects on a lipopolysaccharide (LPS) inflammation model (42). Results 
from this study found that mice fed a diet high in both total PUFA and ratio of n-6 to n-3 fatty 
acids, had an increased systemic inflammatory response. Given this information, the potential 
link between dietary PUFA concentration and n-6:n-3 ratio was studied further. In the current 
study, we specifically examined the effect of high (10% kcal) and low (2.5% kcal) PUFA content 
along with high (20:1) and low (1:1) ratios of n-6 to n-3 fatty acids on gut inflammation and the 
subsequent impact on colorectal cancer risk using an AOM + DSS mouse model of CRC. 
Based on the preliminary data, we hypothesized that a diet with high PUFA concentration and 
high n-6:n-3 ratio would increase tumor multiplicity and size compared to the low PUFA, low n-
6:n-3 diet and the control AIN diet. The specific aims for this study include: 
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1. Determine the impact of five different experimental diets on colon cancer susceptibility 
using an AOM + DSS inflammation model of colorectal carcinogenesis. The 
experimental diets were as follows: 
Diet 1: AIN-93G basal diet: 7% energy from PUFA, 7:1 n-6 to n3 ratio (Control)  
Diet 2: AIN-93G basal diet: 2.5% energy from PUFA, 1:1 n-6 to n-3 ratio 
Diet 3: AIN-93G basal diet: 2.5% energy from PUFA, 20:1 n-6 to n-3 ratio 
Diet 4: AIN-93G basal diet: 10% energy from PUFA, 1:1 n-6 to n-3 ratio  
Diet 5: AIN-93G basal diet: 10% energy from PUFA, 20:1 n-6 to n-3 ratio 
2. Compare the serum cytokines levels for TNF-α, INFγ, IL-17, IL-10, and IL-6, along with 
CRP, in mice fed experimental diets in both the control and cancer treatment groups. 
3. Determine the effect of the experimental diets on fecal metabolites and the fatty acid 
profile of red blood cell and colon mucosal membranes. 
 
Total Western Diet-2 
 To date, a whole-food based rodent diet that appropriately matches American eating 
patterns both on the macro- and micronutrient level has not been developed. The specific 
objective of this project is to effectively develop a functioning whole-food based rodent diet. Data 
from the NHANES survey What We Eat in America for the years 2007-2008 (25) and the Retail 
Food Commodity Intakes: Mean Amounts of Retail Commodities per Individual, 2001- 2002 (43) 
was used in the formulation of the TWD-2.  Initiating studies using the TWD-2, in place of the 
AIN diets, will hopefully make the rodent a better model for colorectal cancer and microbiome 
research. 
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CHAPTER 2 
EFFECTS OF DIETARY POLYUNSATURATED FATTY ACIDS ON  
COLORECTAL CANCER 
 
Abstract 
 The Western diet is characterized by consuming a diet high in red and processed meats, 
refined grains, and sugars. This type of eating pattern results in an increased consumption of 
omega 6 fatty acids and a shift to a higher ratio of omega 6 (n-6) to omega 3 (n-3) fatty acids. 
Eicosanoids derived from n-6 fatty acids have been shown to induce a pro-inflammatory response 
in the body; while n-3 derived eicosanoids have an anti-inflammatory effect. The aim of this 
study was to determine if high dietary concentrations of total polyunsaturated fatty acids (PUFA) 
or the unbalanced ratio of n-6:n-3 found in Western diet would promote the development of 
colorectal cancer (CRC) using the AOM + DSS induced inflammatory model.  Five different 
diets, which varied only in the dietary PUFA concentration and n-6 to n-3 ratio, were fed to mice. 
The diets used were 1.) AIN-93G control diet, 7% (kcal) dietary PUFA 7:1 n-6:n-3 ratio, 2.) 2.5% 
dietary PUFA 1:1 n-6:n-3 ratio, 3.) 2.5% PUFA 20:1 n-6:n-3, 4.) 10% PUFA 1:1 n-6:n-3, and 5.) 
10% PUFA 20:1 n-6:n-3.  The investigated outcomes included tumorigenesis, systemic 
inflammation, fatty acid analysis of red blood cell and colon mucosal membranes, and fecal 
metabolite analysis.  Mice fed the AIN-93G and the 2.5% PUFA with 1:1 ratio of n-6 to n-3 diets 
had significantly higher colon tumor multiplicity (p < 0.0001) than mice fed the other diets. The 
dietary n-6:n-3 ratio but not the PUFA concentration had a significant effect on tumor size.  Mice 
fed diets with a PUFA ratio of 1:1 had significantly larger tumors than mice fed diets with a 
PUFA ratio of 20:1 (p-value = 0.027).   Diets with higher PUFA concentrations appeared to 
influence the systemic inflammatory response of TNF-α, IL-17, and IL-10.  The fecal metabolite 
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profile was affected by both the dietary PUFA ratio and concentration, as well as AOM treatment. 
Our results suggest both the PUFA concentration and PUFA ratio influence the etiology of CRC. 
Specifically, higher ratios of n-6:n-3 dietary PUFA appear to be protective against AOM + DSS 
induced tumorigenesis. 
 
Introduction 
 The essential fatty acids, linoleic acid (LA, C18:2n-6) and -linolenic acid (ALA, 
C18:3n-3), must be obtained from the diet, as they cannot be synthesized de novo.  In Western 
populations, the consumption of these two fatty acids has changed dramatically in the last 100 
years. This change has resulted in an increase in the n-6:n-3 ratio, which studies suggest may 
result in detrimental health effects through excessive eicosanoid signaling (6, 7). Once in the 
body, LA and ALA are further elongated and desaturated through the delta-6-desaturase/delta-5- 
desaturase (D6D/D5D) enzymatic pathway, producing their respective highly unsaturated fatty 
acids: arachidonate (AA, C20:4n-6), eicosapentaenoate (EPA, C20:4n-3), and docosahexaenoate 
(DHA, C22:6n-3) (44). The average American diet contains substantially more LA than ALA. 
Consequently, this difference is reflected in the tissue PUFA content, with Americans exhibiting 
a greater proportion of AA compared to EPA in their adipose tissue (45). AA and EPA can be 
further converted to eicosanoid signaling molecules through one of two enzymatic pathways, 
cyclooxgenase (COX) or lipoxygenase (LOX), both of which are upregulated during the 
inflammatory state. The process by which these enzymes recognize and activate the n-6 or n-3 
fatty acids appears to be nonspecific, suggesting the fatty acids are released based on their relative 
proportions in the membrane (37).  Metabolites derived from AA are considered to have a 
stronger inflammatory response compared to the n-3, EPA and DHA, derived metabolites (37). 
The long chain omega-6 derived fatty acid, AA, has been shown to produce higher levels of 
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prostaglandin E2 (PGE2) and leukotriene B4 (LTB4) (39, 46).  In colorectal cancer, PGE2 has 
been shown to cause hypermethylation of DNA, reducing the expression of a number of tumor 
suppressor genes (47). LTB4 influences the cellular microenvironment by acting as a growth 
factor and has been found at higher concentrations in some cancerous tissues (46). The 
prostaglandins and leukotrienes produced from omega-3 derived fatty acids through the 
LOX/COX pathway, LTB5 or PGE3, have been shown to have anti-inflammatory effects (37, 39). 
Production of PGE3 will decrease the production of PGE2, thus preventing this prostaglandin 
from promoting cell proliferation. PGE3 has also been shown to down-regulate the expression of 
the enzyme COX-2 required for PGE2 production (48).  Investigations have found that by 
incorporating EPA into the diet in its free fatty acid form results in less tumor multiplicity 
compared to mice fed a diet containing no EPA (39). 
 Another factor contributing to the development of CRC is an abnormal increase in a 
systemic response of the following cytokines: IL-6, TNF-α, IL-10, IL-17, and INFγ (49-51). 
Elevated levels of IL-6, IL-17, and TNF-α have been measured in individuals with chronic gut 
inflammatory conditions.  Elevation of these cytokines promotes carcinogenesis through 
overactive signaling causing further pro-inflammatory responses, increased cell proliferation, and 
tumor growth (49, 50).  IL-6 will stimulate production of C-reactive protein (CRP), an acute- 
phase protein, inducing a pro-inflammatory response in the body (52). The role of INF  in the 
etiology of cancer is somewhat controversial. INFγ was believed to act in an anti- 
inflammatory/anti-tumorigenic way by increasing tumor immunogenicity through the 
upregulation MHC class I genes (53).  Current thinking is that this cytokine actually decreases 
tumor immunogenicity through the down-regulation of tumor antigen expression. Without this 
expression, tumors do not stimulate an immune response, allowing further growth and 
14 
 
development (51).  IL-10 plays an important role in regulating inflammation corresponding to 
colon cancer, through controlling cell growth and preventing tumor development (54). 
 Individuals with IBD or colorectal cancer have a number of factors affecting the etiology 
of these diseases. Not only do they have an increase in inflammatory cytokine and eicosanoid 
signaling, but studies have shown they also exhibit changes in their gut microbiome as compared 
to healthy individuals (33). Through 16s sequencing, researchers were able to compare bacterial 
phyla present in patients with CRC and healthy individuals. Their findings showed healthy 
individuals had a statistically higher amount of Bacteroidetes and statistically lower amount of 
Proteobacteria.  At the genus level, CRC patients had a larger population of five different genera 
compared to healthy individuals including: Porphyromonas, Escherichia/Shigella, Enterococcus, 
Streptococcus, and Peptostreptococcus (33).   A separate study suggests the members of the 
Fusobacterium genus may play a role in CRC, as this type of bacterium has been found at higher 
concentrations in tumor tissue (55). The bacteria present in the gut will produce metabolic 
substrates that may be beneficial or harmful to the host.  For example, certain bacteria can 
produce metabolites such as acetaldehyde, hydrogen sulfide, or secondary bile acids that are 
believed to contribute to inflammation and tumor progression (33). One specific metabolite that 
has been shown to have a protective effect against CRC is butyrate. Butyrate has been shown to 
reduce oxidative damage to DNA and decrease CRC progression by inducing apoptosis and 
inhibiting tumor cell growth. Patients with CRC have been found to have less butyrate-producing 
bacteria compared to healthy individuals (33). 
 To examine the potential role of PUFA on gut inflammation and its role in the 
progression of CRC, plant derived dietary PUFAs, LA and ALA, were used to formulate diets 
differing in PUFA concentration and n-6:n-3 ratio. To date, plant derived dietary PUFA and the 
ratio of n-6 to n-3 has not been investigated in colorectal cancer rodent models. Considering that 
plant derived dietary PUFA accounts for 99% of the daily PUFA intake in Americans, it is critical 
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to understand the effects of these fatty acids on gut inflammation and ultimately their role in 
colorectal cancer in order to develop appropriate intervention strategies relevant to American 
diets (56). To investigate the effects of dietary PUFA on inflammation, gut metabolites, and CRC 
occurrence, mice were subjected to an AOM + DSS inflammatory challenge and fed diets that 
varied only in the percent of PUFA and ratio of n-6 to n-3 fatty acids. While the experimental 
diets represented some of the highest and lowest dietary PUFA concentrations and n-6:n-3 ratios 
reported, the control AIN-93G, allowed us to observe the effect of an intermediate level of dietary 
PUFA concentration and n-6:n-3 ratio, having 7% PUFA and n-6:n-3 ratio of 7:1. The 
experimental endpoints measured were tumor development and inflammation, serum cytokine 
levels, fatty acid profiles of red blood cells and colon mucosa, and fecal metabolite profiles.  
  
Methods 
 
Experimental Design 
 Five-week-old male C57BL/6J mice were purchased from Jackson Laboratory and 
allowed to acclimate for one week at Utah State University’s Laboratory Animal Research 
Center. At six weeks of age, mice were randomly assigned to one of five experimental diets 
(Harlan Teklad) for a feeding period of 16 weeks: 1.) AIN-93G control diet, 2.) 2.5% (kcal) 
dietary PUFA 1:1 n-6:n-3 ratio, 3.) 2.5% PUFA 20:1 n-6:n-3, 4.) 10% PUFA 1:1 n-6:n-3, and 5.) 
10% PUFA 20:1 n-6:n-3.  The fatty acid profiles of these experimental diets are depicted in table 
3. 
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TABLE 3. Fatty acid composition of experimental diets 
 Target Values Measured Values a 
Diet PUFA % Ratio  16:0 18:0 18:1 18:2 18:3 SFA MUFA PUFA Ratio 
1 7.0 7:1 1.2 0.5     2.5 5.7 0.8 1.7  2.5  6.4  7:1 
2 2.5 1:1 2.8 2.8 8.4 1.5 1.4 5.6  8.4  2.8  1:1 
3      2.5 20:1 2.4 1.7   10.2 2.4 0.2 4.1 10.2  2.5     16:1 
4    10.0 1:1 2.2 1.1     3.7 5.3 4.8 3.3  3.7 10.0  1:1 
5    10.0 20:1 2.7 0.8 4.5 8.5 0.4 3.5  4.5  8.8     24:1 
a Values are expressed as percent total dietary energy. 
 
Mice were then randomly distributed into the following treatment groups, AOM injection and 
DSS treated drinking water (n = 20) for the cancer outcome or saline injection and regular 
drinking water (n = 6) for the sham or control outcome.  Sham treated animals were individually 
housed and the mice in the cancer treatment were co-housed.  Animals had access to food and 
drinking water ad libitum.  At seven weeks of age, cancer outcome mice were subcutaneously 
injected with a single, 10 mg/kg dose of AOM and administered drinking water containing 1% 
DSS for four weeks to facilitate tumorigenesis (57).  Control mice received a subcutaneous 
injection of 10 mg/kg of saline and standard drinking water was administered throughout the 
study. At 16 weeks of age, all mice were euthanized via CO2 asphyxiation and cardiac puncture. 
Serum was collected using serum collection spin tubes (Sarstedt AG & Co) and flash frozen using 
liquid nitrogen.  For metabolomic analysis, feces from the colon were collected and flash frozen 
using liquid nitrogen. The Institutional Animal Care and Use Committee (IACUC) of Utah State 
University approved all study procedures. The protocol number was 2217. 
 
Tumor Analysis 
 The lower bowel, from below the cecum to the rectum, of AOM + DSS treated mice was 
removed to assess the impact of experimental diets on tumor multiplicity.  Colons were washed 
with saline, split longitudinally, laid flat on filter paper, and stored in 70% ethanol at 4°C. To 
determine tumor multiplicity and size, colons were stained with methylene blue to aid in the 
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characterization of tumors by light microscopy.  To determine tumor size, calipers were used to 
measure the length, width, and height. Using these measurements the volume was calculated 
using the equation V= /6 (L x W x H).  
 
Systemic Inflammation 
 Known cytokines and acute phase proteins involved with gut inflammation and IBD were 
measured using custom multiplex ELISA assays purchased from Milliplex.  The following serum 
cytokines: INF-, IL-6, IL-10, IL-17, and TNF-α, in-junction with the acute phase protein, C-
reactive protein (CRP), were measured.  Protocols suggested by the manufacturer and a Bio-Plex 
200 instrument equipped with the Bio-Plex Manager 5.0 software were used to analyze data.   
 
GC-MS Analysis of Fecal Metabolites 
 The sample preparation protocol and GC-MS temperature program were adapted from 
Hintze et al. (58).  Fecal pellets were broken up in 1 mL of 70% ethanol (v/v) + 1 mg/mL D4-
succinate (Sigma-Aldrich, Co).  D4-succinate was used as the internal standard.  Samples were 
heated at 90°C for 5 min and then centrifuged at 5,000 x g for 5 min.  Supernatant was removed 
and dried down under vacuum. Dried samples were suspended in 40 L of 40 mg/mL O-
methoxylamine hydrochloride in pyridine and incubated for one hour at 30°C.  Following 
incubation, 40 L of N-Methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA) was added to each 
sample and incubated for 30 min at 37°C with vortexing every 5 min.  A 1 L sample was 
injected into the gas chromatograph at a 10:1 split ratio with an inlet temperature held at 250°C.  
The temperature program started at 70°C for 1 min, followed by a 40°C/min-ramp to 110°C, with 
a 2 min hold at 110°C.  A second ramp of 5°C/min-ramp was carried to a final temperature of 
350°C (58).  Helium was used as the carrier gas and separation was performed on a ZB-5 MSI 
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column (35 m length, 0.25 mm diameter and 0.25 m film thickness).  A GC-2010 (Shimadzu) 
gas chromatograph fitted with a GC-MS QP2010S (Shimadzu) mass spectrometer was used in 
this analysis.  Compounds were identified using SpectConnect, Automated Mass Spectral 
Deconvolution and Identification System (AMDIS) software and the National Institute of 
Standards and Technology (NIST) mass spectral library.  Peak areas were normalized to the 
internal standard and metabolite values were expressed as a ratio.   
 
Fatty Acid Analysis of Red Blood Cells and Colon Mucosa 
 To analyze fatty acids present in colon mucosa and red blood cell (RBC) samples, direct 
fatty acid methyl ester (FAME) synthesis was conducted according to O’Fallon et al. and samples 
were analyzed using a GC2010 (Shimadzu) (59).  Due to the small amount of RBC’s available, 
solvents used for RBC preparation were diluted by factor of 10.  A 1 µL sample was injected into 
the gas chromatograph at a 10:1 split ratio with an inlet temperature held at 250°C.  The 
temperature program started at 153°C for 2 min, followed by a 2.3°C/min-ramp to 174°C, with a 
hold time of 20 sec.  A second temperature increase of 2.5°C/min-ramp to a final temperature of 
210°C, which was held for 5 min.  Separation was performed on a DB-23 column (30 m length, 
0.25 mm diameter and 0.25 m film thickness) using helium as the carrier gas.  
 
Statistical Analysis 
 JMP statistical software, version 11.0 (SAS Institute Inc.) was used to conduct the 
statistical analysis on all experimental endpoints.  One-way and two-way analysis of variance 
(ANOVA) was used to evaluate statistical differences between experimental diets and 
investigated endpoints.  One-way ANOVA was used to determine statistical differences between 
all experimental diets, including the control and two-way ANOVA was used to determine if 
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statistical differences were occurring between the main effects of PUFA concentration and PUFA 
ratio. Tukey-Kramer HSD post hoc analysis was used to test for pair-wise comparisons via one- 
way ANOVA and Student’s t-test was used for paired comparison for the two-way ANOVA.  All 
experimental endpoints were calculated as mean ± standard error, unless otherwise noted.  SAS 
statistical software (version 9.4) was used for the principal component analysis.  Statistical 
significance was predefined as a p-value < 0.05. 
 
Results  
 
Effect of Treatment and Weight Gain 
 Weights of the control and AOM + DSS treated mice in each diet were tracked 
throughout the feeding portion of the experiment.  Diet treatment had no significant effect on 
weight gain in the sham treated mice.  However, the AOM + DSS treated mice fed the AIN-93G 
diet had significantly higher weight gain than those fed the 2.5% 20:1, 10% 1:1, or 10% 20:1 
diets (p-value < 0.05) (Figure 1). There was no significant difference in food consumption 
between any of the experimental diets.  Over the course of the experiment, seven deaths occurred 
within the AOM + DSS treated mice (n= 2 – AIN-93G, n= 1 - 2.5% 20:1, n= 3 - 10% 1:1, and n= 
1 - 10% 20:1). Deaths occurred either early on or late in the feeding portion of the study.  Early 
deaths were caused by AOM toxicity, while the deaths that occurred late in the feeding study, 
were likely due to advanced tumor development resulting in obstruction of the bowel. At 
euthanization a number of AOM + DSS treated mice had a prolapsed anus likely caused by 
advanced tumor development in the distal colon. 
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 FIGURE 1. Weight gain of the AOM + DSS treated mice.  Different lettered columns 
indicate a significant difference between experimental diets (p-value <0.05), which were 
determined by one-way ANOVA and Tukey-Kramer HSD post hoc analysis. Values for are 
expressed as mean  standard error.  
 
Effect of Experimental Diets on Tumor Multiplicity and Size  
 To assess cancer progression, tumors were identified based on the nomenclature accepted 
in the consensus report by Boivin et al. (18). There was a significant increase in tumor 
multiplicity (p-value < 0.0001) in mice fed either the 2.5% 1:1 or AIN-93G diets compared to 
mice fed any of the other experimental diets (Figure 2A).  However, when tumor multiplicity was 
normalized to colon length, there was not a significant difference between diet treatments (Figure 
2C). There was a significant main effect of larger tumor size for the n-6 to n-3 ratio but not PUFA 
concentration.  Animals fed diets with a PUFA ratio of 1:1 had significantly larger tumors than 
animals fed diets with a PUFA ratio of 20:1 (p-value= 0.012) (Figure 2F). There was a significant 
difference between experimental diets on mouse colon lengths (p-value = 0.027), however when 
individual treatments were compared via post hoc analysis, there were no significant differences. 
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There was a significant interaction between, PUFA concentration and PUFA ratio, on colon 
length (p-value = 0.017) (Figure 2G). 
 
Effect of Experimental Diets on Serum Cytokines 
 The effect of the experimental diets on the systemic pro-inflammatory response was 
determined by measuring serum levels of the following cytokines: INF-γ, IL-6, IL-10, IL-17, 
TNF-α, and C-reactive protein (CRP) in AOM + DSS treated mice.  Levels of IL-10 and IL-6 
were significantly higher in mice fed the AIN-93G diet than those fed the 10% 20:1 diet (p- 
value= 0.03 and p-value= 0.004, respectively) (Figure 3A & 3D). Levels of TNF-α were 
significantly higher in mice fed the 2.5% 1:1 diet compared to those fed the 10% 1:1 diet (p- 
value= 0.03) (Figure 3B).  IL-17 was significantly higher in the serum of mice fed the AIN-93G, 
2.5% 1:1, and 2.5% 20:1 diets compared to mice fed the 10% 20:1 or 10% 1:1 diets (p-value < 
0.001) (Figure 3C).  C-reactive protein was significantly higher in the serum mice fed either 10% 
1:1 or 10% 20:1 diets compared to mice fed the AIN-93G diet (p-value = 0.001 and 0.03, 
respectively) (Figure 3E). There were no significant differences in INF-γ, Figure 3E). The ratio of 
n-6 to n-3 had no effect on serum cytokine or acute phase protein levels.  However, the 
percentage of dietary PUFA had a significant effect on the levels of IL-10, IL-17, and TNF-α.  
Animals fed diets with a PUFA concentration of 2.5% had elevated serum levels of these specific 
cytokines compared to animals on the 10% PUFA diets (p-value < 0.05) (Figure 4). 
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 FIGURE 2.  Tumorigenic response of mice fed experimental diets and treated with AOM 
+ DSS.  Effects of experimental diets on (A & B) tumor multiplicity, (C & D) mean tumor 
multiplicity/colon length, (E & F) mean tumor size and (G & H) average colon length. Values are 
expressed as mean  standard error. Different lettered columns indicate a significant difference 
between factors (p-value <0.05), which were determined by one-way ANOVA (A), (C), (E), and 
(G) and Tukey-Kramer HSD post hoc analysis or two-way ANOVA (B), (D), (F), and (H) and 
Student’s t-test. 
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 FIGURE 3. Effect of dietary PUFA on systemic inflammation after AOM + DSS 
treatment. Data for: IL-6 (A), TNF- (B), IL-17 (C), CRP (E), and INF-γ(F) are log10 transformed 
mean cytokine or acute phase protein fluorescence  standard error.  IL-10 (D) is mean cytokine 
fluorescence  standard error.  Different lettered columns indicate a significant difference 
between factors (p-value <0.05), which were determined by one-way ANOVA and Tukey-
Kramer HSD post hoc analysis. 
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FIGURE 4. Effect of dietary PUFA ratio and PUFA percentage after AOM + DSS 
treatment.  TNF- (A) and IL-17 (C) are log10 transformed mean cytokine fluorescence  
standard error.  IL-10 (B) is mean cytokine fluorescence  standard error.  Different lettered 
columns indicate a significant difference between factors (p-value <0.05), which were determined 
by two-way ANOVA and Student’s t-test. 
25 
 
Fatty Acid Profile of Red Blood Cells 
 The fatty acid profiles of red blood cells (RBC) from mice on each of the five 
experimental diets, and from both the AOM + DSS and sham treatment were compared.  Figure 5 
depicts the fatty acids that were present at >1% in the RBC membranes.  Animals fed the 10% 
PUFA diets had a significantly higher level of C18:2n-6 in the RBC membranes compared to 
those fed the 2.5% PUFA diets (p-value <0.0001).   Interestingly, the AIN-93G diet, which 
contained only 7% PUFA resulted in significantly higher percentages of C18:2n-6 (p-value < 
0.005) than those on the 10% PUFA diets (Figure 5). While the relative proportion of dietary fatty 
acids in the RBC membranes were influenced by the concentration of PUFA, the n-6 and n- 3 
derived fatty acids: C20:4n-6, C20:5n-3, C22:2n-6, C22:5n-6, and C22:6n-3 were significantly 
affected by the ratio of PUFA in the diet (p-value < 0.0001). It should be noted, C18:3n-3 did not 
contribute >1% of the total fatty acids present in RBC membranes for any of the experimental 
diets, but higher percentages of the n-3 derived highly unsaturated PUFAs, EPA and DHA were 
observed (Figure 5).  Compared to the AOM + DSS treated mice, shams had a higher percent of 
C18:0, C18:1n-9, C18:2n-6 and C20:3n-6 (p-value < 0.0001, p-value = 0.04, p-value < 0.0001, 
and p-value = 0.01, respectively). 
 
Fatty Acid Profile of Colon Mucosa 
 The effect of the experimental diets on the fatty acid profile of colon mucosa from the 
AOM + DSS initiated mice was also analyzed.  Animals fed the 10% 20:1 diet or the AIN-93G 
diet had a significantly higher level of C18:2n-6 in their colon mucosa compared to those fed the 
2.5% PUFA diets.  Significantly higher amounts of C18:1n-9 were measured in animals on the 
2.5% PUFA diets compared to the 10% PUFA diets. Approximately 80% of the fatty acids 
present in the colon mucosa were C16:0, C18:1n-9 or C18:2n-6 (Figure 6), while none of the 
highly unsaturated n-6 or n-3 derived fatty acids were observed at percentages greater than 1%. 
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 FIGURE 5. Fatty acid profile of red blood cells from mice fed experimental diets.  Only 
fatty acids present at >1% of total fatty acids are shown. Values are expressed as percent of total 
fatty acids  standard error. Different lettered columns indicate a significant difference between 
factors (p-value <0.05), which were determined by one-way ANOVA and Tukey-Kramer HSD 
post hoc analysis.  
 
 
 FIGURE 6. Fatty acid profile of colon mucosa from mice fed experimental diets.  Only 
fatty acids present at >1% of total fatty acids are shown. Values are expressed as percent of total 
fatty acids  standard error.  Different lettered columns indicate a significant difference between 
factors (p-value <0.05), which were determined by one-way ANOVA and Tukey-Kramer HSD 
post hoc analysis. 
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Fecal Metabolome Analysis  
 GC-MS analysis of fecal samples from both the sham and AOM + DSS treated animals 
detected 98 compounds, of which 57 were positively matched to the NIST library (Tables 4 & 5 
and Tables 8 & 9).  A majority of these metabolites belong to the following classes: amino acids, 
organic acids, fatty acids, nucleic acids, and organic molecules.  Of the 98 detected compounds, 
41 were considered “unknowns” due to the inability to positively match retention indexes (RI) to 
the NIST database (Table 6 & 7 and Tables 10 & 11).  Statistical analysis using one-way 
ANOVA revealed the experimental diets had a significant effect on five metabolites from the 
sham mice and eight metabolites from the AOM + DSS treated mice (Table 4 & 5).  When 
analyzing the data by treatment group, sham or AOM + DSS, treatment had a significant effect on 
15 metabolites.  AOM + DSS treated mice had a significantly higher amount of the following 
metabolites: acetic acid, L-proline, L-aspartic acid, D-(-)-Rhamnose, benzeneacetic acid, 
butanedioic acid, and N-acetyl-D-glucosamine (p-value < 0.05).  Sham mice had significantly 
higher amounts of: dopamine, docosanoic acid, 5-methyl-pyrimidine, adenine, and tetracosanoic 
acid (p-value < 0.05). The principal component analysis (PCA) of the positively identified 
metabolites showed distinct separation of the AOM + DSS treated and sham mice (Figure 7 & 
10). There was distinct separation of experimental diets based on the dietary PUFA ratios in both 
the PCA plots for the sham and AOM + DSS treated mice (Figure 8 &9). In the sham treated 
mice, the 10% 1:1 diet was closely associated to a majority of the metabolites, while the AIN- 
93G diet was clearly separate from the detected metabolites (Figure 8). However, in the AOM + 
DSS treated mice, AIN-93G was clustered closely with a majority of metabolites (Figure 9). 
Plotting individual mice within each experimental diet (Figure 10) we see separation between 
AOM + DSS and sham treated mice, along with some minor clustering of mine within similar 
experimental diets. 
  
 FIGURE 7.  Principal component analysis for fecal metabolites found in mice fed different experimental diets.  Principal components 
(PC) were determined based on the variation between the average amounts of each individual metabolite detected in response to different 
experimental diets.  The experimental diets were plotted with respect to the PC’s determined from the metabolites. The fecal samples were 
analyzed using GC-MS and metabolites were identified using AMIDS and NIST mass spectral library.  SAS was used to develop the PCA plots.  
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  FIGURE 8.  Principal component analysis for fecal metabolites found in sham treated mice fed different experimental diets. Principal 
components (PC) were determined based on the variation between the average amounts of each individual metabolite detected in response to 
different experimental diets.  The experimental diets were plotted with respect to the PC’s determined from the metabolites. The fecal samples 
were analyzed using GC-MS and metabolites were identified using AMIDS and NIST mass spectral library.  SAS was used to develop the PCA 
plots. 
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  FIGURE 9.  Principal component analysis for fecal metabolites found in AOM + DSS treated mice fed different experimental diets. 
Principal components (PC) were determined based on the variation between the averages amounts of each individual metabolite detected in 
response to different experimental diets.  The experimental diets were plotted with respect to the PC’s determined from the metabolites. The fecal 
samples were analyzed using GC-MS and metabolites were identified using AMIDS and NIST mass spectral library.  SAS was used to develop the 
PCA plots. 
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  FIGURE 10.  Principal component analysis for the fecal metabolomic profiles of mice fed different experimental diets.  Principal 
components (PC) were determined based on the variation between each individual mouse’s metabolomics profile.  The fecal samples were 
analyzed using GC-MS and metabolites were identified using AMIDS and NIST mass spectral library.  SAS was used to develop the PCA plots. 
3
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TABLE 4. Identified metabolites significantly different in sham mice 
Metabolites LRI2 Diet Treatment – Sham      
AIN-93G1 2.5% 1:11 2.5% 20:11 10% 1:11 10% 20:11 SEM p-value 
Acetic Acid 1107     9.80ab      23.00ab   14.88ab 32.14a     8.14b     5.51 0.027 
Benzoic Acid 1522       0.49b       0.85b     7.20ab 10.38a     0.57b     2.04 0.004 
Benzeneprop-
anoic Acid 1736       3.60b     16.38b    1.81b 54.89a     6.97b     9.17 0.002 
Oleic Acid 2211 242.32b 1612.52a 698.36ab 440.57ab 339.08b 297.09 0.021 
Octadecanoic 
Acid 2235 557.84b 3329.22a 2851.16ab 1350.05ab 961.49ab 664.12 0.025 
a,b,c,d Different lettered superscripts within a row indicate significant difference between mean 
values (p-value < 0.05) determined by one-way ANOVA and Tukey-Kramer HSD post hoc 
analysis 
1 Values are expressed as mean ratio 
2 Linear retention index 
 
 
 
TABLE 5. Identified metabolites significantly different in AOM + DSS mice 
Metabolites LRI2 Diet Treatment – AOM+ DSS     
AIN-93G1 2.5% 1:11 2.5% 20:11 10% 1:11 10% 20:11 SEM p-value 
Hexadecanoic 
acid 2047  1644.42  2907.51 2720.59 1396.94   690.81 541.21   0.04 
Oleic Acid 2211    634.67ab 1270.62ab  1758.82a    330.86b 169.97b 290.16   0.003 
Octadecanoic 
Acid 2235  1355.93bc 2910.55a   1894.96ab 
  
1070.40bc 416.81c 353.26  0.0006 
Eicosanoic 
acid 2410 157.51 160.90  162.28  91.78  63.15   26.52   0.03 
Docosanoic 
acid 2571  138.71a   39.12b    17.78b   31.10b   38.48b   15.95 <0.0001 
Cholesteryl 
acetate 2772  47.99 59.80  12.49  30.95  11.12   12.37 0.037 
Butanoic 
Acid 1179  23.19   3.46  23.34   7.10    5.61    5.49 0.029 
Tetracosanoic 
Acid 2724  27.50a    2.18b     4.33b    3.18b     8.16ab   4.95 0.007 
a,b,c,d Different lettered superscripts within a row indicate significant difference between mean 
values (p-value < 0.05) determined by one-way ANOVA and Tukey-Kramer HSD post hoc 
analysis 
1 Values are expressed as mean ratio 
2 Linear retention index 
33  
 
 
TABLE 6. Unknown metabolites significantly different in sham mice 
Unknown 
Metabolites 
LRI Diet Treatment - Sham     
AIN-93G 2.5% 1:1 2.5% 20:1 10% 1:1 10% 20:1 SEM p-value 
Unknown 1  2831 2.072ab 3.415ab 9.639ab 13.866a 0.000b 3.21 0.027 
a,b,c,d Different lettered superscripts within a row indicate significant difference between mean 
values (p-value < 0.05) determined by one-way ANOVA and Tukey-Kramer HSD post hoc 
analysis 
1 Values are expressed as mean ratio 
2 Linear retention index 
 
 
 
 
 
 
TABLE 7. Unknown metabolites significantly different in AOM + DSS mice 
Unknown 
Metabolites 
LRI Diet Treatment – AOM + DSS   
 AIN-93G 2.5% 1:1 2.5% 20:1 10% 1:1 10% 20:1 SEM p-value 
Unknown 2 2264 19.674ab 24.928a 5.656ab    0.000b 3.800ab 5.43 0.012 
Unknown 3  2847    50.382a 0.000b       1.409b   12.486ab       1.773b 10.24 0.008 
Unknown 4 3027   201.503    11.527        0.000 145.479   13.587 53.09 0.035 
a,b,c,d Different lettered superscripts within a row indicate significant difference between mean 
values (p-value < 0.05) determined by one-way ANOVA and Tukey-Kramer HSD post hoc 
analysis 
1 Values are expressed as mean ratio 
2 Linear retention index 
 
Discussion 
 
 Previous work by our group (unpublished data) and others (60) suggests that dietary 
PUFA concentrations and ratios play a role in gut inflammation and possibly the development of 
CRC.  To further investigate these findings, experimental diets that were identical except for 
varying PUFA concentration and ratios of n-6 to n-3, were fed to mice.  CRC development was 
assessed using the AOM + DSS model.  Based on our preliminary data, we hypothesized that 
mice fed a diet with a low concentration of PUFA and a low n-6:n-3 ratio would be protected 
from CRC compared to mice fed a diet with a high concentration of PUFA and a high n-6:n-3 
PUFA ratio. However, contrary to our hypothesis, animals fed either the AIN-93G or the 2.5% 
1:1 diets had a higher colon tumor multiplicity compared to animals fed the other three 
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experimental diets.  Yet, when tumor multiplicity was normalized to colon length, there was no 
longer a significant difference between diet treatments. Colon length was used to evaluate gut 
inflammation, as studies have shown colon length and gut inflammation have an inverse 
relationship (13, 57). Our data showed a significant interaction between the main effects of PUFA 
concentration and PUFA ratio on colon length (p-value = 0.017) (Figure 2H).  However, there 
were no significant differences between experimental diets when compared via post hoc analysis.  
Our hypothesized inflammatory diet, 10% 20:1, did trend toward the shortest colons compared to 
mice fed the other experimental diets, but it also trended toward the smallest mean tumor size.  In 
our study, the ratio of PUFA had a more significant impact on tumor size than the percent of 
PUFA, with diets having a PUFA ratio of 1:1 resulting in larger tumors compared to mice fed 
diets with a PUFA ratio of 20:1. Interestingly, animals fed the intermediate diet, AIN- 93G (7% 
PUFA and 7:1 n-6:n-3 ratio) had the highest number of tumors and the second highest tumor 
severity amongst the other experimental diets. This is relevant as the average American diet has a 
dietary PUFA concentration 8% and an n-6:n-3 ratio of 10:1 (61).  In a similar study, it was 
reported that rats fed a high-fat diet containing a diverse fatty acid profile, similar to the Western 
diet, resulted in significantly higher tumor incidence, compared to rats fed a diet high in long 
chain n-3 fatty acids, EPA and DHA, in response to AOM (60). This study suggested that both 
the amount and the type of dietary fatty acid play a role in the etiology of CRC.  Many studies 
investigating the effects of dietary n-6 and n-3 fatty acids in CRC use experimental diets 
containing the highly unsaturated 20- and 22-carbon forms of n-6 and n-3, like AA, EPA, and 
DHA (39, 60). In our study, the experimental diets used contained n-6 and n-3 fatty acids in their 
18-carbon form, LA or ALA.  We incorporated the 18-carbon forms of n-6 and n-3 in the 
experimental diets because approximately 99% of the dietary PUFA consumed by Americans is 
in this form (56).  Using the 18-carbon forms of n-6 and n-3 fatty acids will allow the dietary fatty 
35 
 
acids to follow a similar desaturation pathway that occurs in humans and allow us to observe any 
changes that may occur in this pathway in response to AOM + DSS. 
Previous work has demonstrated that membrane fatty acid profiles are reflective of the 
relative proportion of dietary fat consumed (38-40).  Our study confirmed these findings, as 
dietary fat intake directly influenced the fatty acid profile of RBC membranes and colon mucosa. 
Previous studies have suggested the fatty acid distribution of certain membranes can influence 
disease occurrences, such as coronary heart disease and CRC (38, 40, 41).  In the fatty acid 
profiles of the RBCs, the ratio of PUFA in the diet significantly influenced the fatty acid 
membrane composition for the highly unsaturated fatty acids: C20:4n-6, C22:4n-6, C22:5n-6, 
C22:5n-3, and C22:6n-3.  Data from others would suggest the experimental diets that resulted in 
higher percentages of AA would produce higher levels of the pro-inflammatory eicosanoids, 
PGE2 and LTB4, in these animals (46).  In a study, rats fed a diet high in n-6 fatty acids resulted 
in higher COX-2 expression and AA derived eicosanoids, compared to rats fed a low-fat or high 
n-3 fatty acid diet (60).  Hawcroft et al. found a significant decrease in PGE2 in mice fed a diet 
containing 5% EPA compared to a diet with no EPA (39).  Animals in our study that were fed the 
high n-6:n-3 PUFA ratio diets showed higher percentages of AA in their RBC membranes.  
However, these diets did not result in an increased tumorigenic response. Measuring the levels of 
AA derived eicosanoids and COX-2 expression is needed to give us a better understanding of the 
inflammatory response to these experimental diets.    
 A study by Coviello et al. found patients with CRC had a significantly higher ratio of n- 
6:n-3 fatty acids and lower amount of n-3 and n-3 derived fatty acids incorporated into their RBC 
membranes compared to healthy individuals (41). Our results followed a similar trend, where the 
AOM + DSS treated mice had a higher n-6:n-3 ratio in their RBC membranes compared to the 
sham mice, however, this difference was not statistically significant. The fatty acid profile in the 
colon mucosa was quite different from the profile found in the RBC analysis, with a significantly 
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higher percentage of the unsaturated fatty acids: C14:0, C16:0, and C20:0, the mono-unsaturated 
fatty acids: C16:1c-9, C18:1n-7, C18:1n-9, and C20:1n-9, and the PUFAs: C18:2n-6 and C18:3n-
3, in colon mucosa.  None of the highly unsaturated fatty acids that were present in the RBC 
membranes were observed in colon mucosa at >1%.  Changes in the distribution of fatty acids 
between RBC membranes and other tissues including, liver (40), adipose (62), and colon mucosa 
(63, 64) have been reported.  In another study, similar results were reported when the fatty acid 
profile of intestinal polyps were evaluated.  When they compared intestinal polyps to normal 
colon mucosa, a higher ratio of saturated fatty acids to PUFA tended to occur in polyps (63). 
  The systemic inflammatory response from these experimental diets did not support our 
proposed hypothesis. There was an inverse correlation between cytokine levels and PUFA 
concentration regardless of the n-6:n-3 PUFA ratio, for IL-10, IL-17, and TNF-α (Figure 4). Our 
data suggests there is a threshold in regard to the dietary PUFA concentration in promoting a pro- 
inflammatory response (Figure 3).   Mice fed the AIN-93G control diet, containing 7% PUFA and 
a 7:1 n-6:n-3 ratio, had significantly higher serum levels of the cytokines IL-6, IL-17, and IL-10, 
in response to AOM + DSS induced inflammation, compared to the hypothesized inflammatory 
diet (10% PUFA and 20:1 n-6:n-3 ratio)  (p-value = 0.01, p-value = 0.007, and p-value < 0.0001, 
respectively). In a similar study, the systemic response was measured in mice in response to LPS. 
Mice that were fed the AIN-76A also had elevated serum levels of pro-inflammatory cytokines, 
similar to what we saw from our results (42). The experimental diets in this study and our study 
had a more diverse fatty acid profile compared to either the AIN-93G or AIN-76A diets, which 
use a single source of fat, either soybean or corn oil, respectively. This suggests the type of 
dietary fat can influence the inflammatory response.  Not all cytokines induce an inflammatory 
response; IL-10 plays an important role in regulating inflammation in the body.  In fact, knockout 
IL-10 animals have been shown to spontaneously develop symptoms of IBD (50). In our study, 
mice fed the 10% 20:1 diet had significantly lower serum levels of IL-10 compared to mice fed 
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the AIN-93G diet.  Lower serum levels of IL-10 could indicate why mice fed the 10% 20:1 diet 
tended to have more gut inflammation than mice on the AIN-93G diet.  
  The combination of metabolites produced by the gut microbiota and the metabolites and 
immune response produced by the host can influence colon health and the etiology of CRC (33). 
An examination of the PCA plots provides valuable insight into how the experimental diet 
affected the production of different gut metabolites.  From the PCA analysis, the AOM + DSS 
treatment clearly influenced a separation between AOM + DSS and sham treated mice (Figure 7). 
This separation between AOM +DSS and sham treated mice can also be observed in the PCA plot 
of individual mice (Figure 10).   Dietary PUFA ratio clearly influenced the separation between 
experimental diets and association with certain fecal metabolites. The sham mice fed the 10% 1:1 
diet and the AOM + DSS treated mice fed the AIN-93G diet appeared to be more closely 
associated with a majority of metabolites compared to the other experimental diets (Figure 8 & 
9).  While the AIN-93G was closely associated to metabolites in the presence of AOM + DSS, 
without this induced inflammation the AIN-93G was clearly separated from the detected 
metabolites. Understanding how these metabolites affect colon health is unclear. Studies have 
shown that secondary bile acids are believed to have a negative effect on colon health as patients 
with CRC have been found to have higher levels deoxycholic acid (DCA) (65). Meanwhile, 
SCFA are believed to have a positive influence on colon health, with higher amounts of butyrate- 
producing bacteria found in healthy patients compared to individuals with CRC (33). 
 While the results of this study did not support the proposed hypothesis that a diet high in 
total PUFA with a high n-6:n-3 ratio would promote inflammation mediated CRC, the data 
collected presented some novel findings.  Diets containing a 1:1 n-6 to n-3 ratio had significantly 
larger tumors, suggesting that once dysplastic cells were present, this diet advanced tumor 
growth. Both the type and amount of dietary fat has been shown to play a role in the post- 
initiation stages of colon carcinogenesis (66). The less prevalent tumor development and severity 
38 
 
associated with the 10% 20:1 diet may have been due to lower levels of pro-inflammatory 
cytokines associated with this treatment.  Also of interest, mice fed the control AIN-93G diet had 
significantly higher serum levels of pro-inflammatory cytokines compared to mice in the other 
treatments.  Again, it is important to note that all the experimental diets, including the control 
diet, only varied in the PUFA content and n-6 to n-3 ratio, and the results generated suggest both 
dietary components played a role in carcinogenesis. 
 In summary, mice fed diets with a PUFA ratio of 1:1 had significantly larger tumors 
compared to mice consuming diets with an n-6:n-3 ratio of 20:1 (Figure 2F). The serum cytokine 
levels for IL-10, IL-17, and TNF-α were significantly higher in mice fed diets containing 2.5% 
PUFA compared to mice fed the 10% PUFA diets (Figure 4).  In regard to the fatty acid profiles, 
both the ratio and percent of PUFA influenced distribution of fatty acids in RBC membranes and 
colon mucosa membranes. The highly unsaturated fatty acids were significantly influenced by the 
dietary n-6:n-3 PUFA ratio, while C18:1n-9 and the essential fatty acid, C18:2n-6, were 
significantly influenced by the concentration of PUFA in the diet. Fecal metabolites appeared to 
be influenced by both the dietary PUFA concentration and n-6:n-3 ratio, as well as the AOM + 
DSS treatment.  Our results suggest both the percent and ratio of PUFA play a role in the etiology 
of AOM+DSS induced CRC. Further research is needed to determine how these two factors 
interact and influence gut inflammation and the subsequent impact on CRC. 
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TABLE 8. Identified metabolites in sham mice, supplement 
Metabolites LRI2 Diet Treatment – Sham 
AIN-93G1 2.5% 1:11 2.5% 20:11 10% 1:11 10% 20:11 SEM p-value 
Pryidine 1151 7.25 6.00 15.75 11.42 11.88 5.79   0.76 
3-Pyridinecarboxylic acid 1285 9.30 25.63 19.13 29.25 23.71 7.44   0.39 
4,4’-Bipyridine 1530 22.92 17.80 40.41 29.17 28.47 15.25   0.87 
Propanoic Acid 1099 82.51 430.64 256.09 416.76 300.47 118.86   0.26 
L-Valine 1115 399.80 1026.15 1079.18 1534.28 1175.13 394.29   0.39 
Alanine 1546 71.34 191.95 219.29 254.54 239.91 73.20   0.43 
5-oxo-L-Proline 1527 153.74 443.66 337.52 460.26 433.60 116.28   0.33 
L-Proline 1293 29.03 89.82 57.52 146.61 55.76 30.16     0.094 
L-Glycine 1136 422.33 937.51 974.96 1285.72 1060.38 253.46   0.21 
L-Leucine 1162 345.97 942.07 947.79 1480.09 1007.72 344.72   0.27 
L-Serine 1254 193.46 601.55 585.65 839.26 610.05 184.32   0.21 
L-Methionine 1404 74.27 169.40 201.10 255.25 197.16 64.99   0.40 
L-Aspartic Acid 1422 144.77 350.28 266.81 414.26 317.70 75.37   0.16 
L-Glutamic Acid 1635 182.33 390.33 341.49 521.98 238.97 104.58   0.20 
Phenylalanine 1638 58.47 265.78 199.71 278.68 218.91 95.18   0.51 
L-Tryptophane 2196 23.70 61.23 55.43 99.20 63.61 20.93   0.19 
L-Tyrosine 1890 236.51 738.40 686.92 962.45 707.22 262.29   0.42 
L-Theronine 1291 312.66 512.24 773.91 849.68 855.83 258.52   0.50 
D-Ribose 1713 264.26 718.55 573.07 558.24 478.49 221.27   0.69 
D-(-)-Rhamnose 1759 11.38 64.96 83.74 65.45 55.82 27.66   0.45 
D-Glucose 1934 381.77 1382.61 1973.64 1548.62 1811.88 582.89   0.36 
D-Mannose 2018 118.57 83.98 99.94 104.46 93.22 62.32   0.99 
Glycerol 1274 180.11 418.82 196.98 375.98 269.42 114.77   0.50 
1-O-Octadecylglycerol 2612 1.33 83.96 65.96 174.33 148.27 46.57   0.10 
Dimethylketene 1179 39.96 112.16 102.75 177.65 104.46 34.77   0.13 
Dodecamethyl-
Pentasiloxane 1182 3.74 17.19 25.29 31.27 32.87 12.86   0.50 
Urea 1231 61.01 111.46 178.40 187.72 174.83 49.27   0.32 
Phosphoric acid 1272 7.02 9.27 13.22 10.72 6.65 3.61   0.69 
Dopamine 1358 57.73 190.16 128.35 198.11 329.44 94.65   0.37 
Pryimidine 1335 78.02 153.39 111.37 155.57 108.44 51.54   0.80 
Benzeneacetic Acid 1647 27.79 148.40 70.65 288.35 102.17 66.04 0.087 
Dodecanoic Acid 1655 33.89 62.13 67.60 85.89 63.52 16.26   0.29 
2-Pyrrolidone-5-carboxylic 
Acid 1536 146.67 259.18 259.88 390.44 188.06 88.15   0.38 
9H-Purine 1815 33.93 105.80 77.85 84.82 62.29 33.64   0.64 
Hexadecanoic acid 2047 488.53 3149.95 2438.74 1229.87 1199.92 653.07 0.054 
Linoleic Acid 2205 245.14 158.10 69.63 165.53 153.97 72.77   0.58 
Eicosanoic acid 2410 54.97 208.71 323.14 162.98 145.28 71.69   0.15 
Docosanoic acid 2571 54.13 71.91 131.76 118.45 111.76 35.39   0.50 
Cholesteryl acetate 2772 9.49 62.90 45.10 75.39 48.48 22.48   0.33 
Deoxycholic Acid 3058 49.40 167.37 172.26 285.78 449.84 99.71 0.088 
Benzene 1250 1.61 2.55 5.21 3.72 4.39 2.18   0.78 
Butanedioic Acid 1307 0.00 5.03 2.65 3.22 0.00 2.11   0.40 
Tetradecanoic Acid 1849 8.21 42.89 13.75 15.94 13.40 8.65 0.066 
5-Methyl-Pyrimidine 1401 6.62 20.90 17.10 25.54 22.33 9.34   0.66 
Adenine 1873 5.35 7.02 2.67 6.01 1.15 3.66   0.77 
11-Eicosenoic acid 2388 0.00 124.53 17.60 104.38 97.42 39.96   0.13 
Pentadecanoic Acid 1915 6.86 27.10 37.49 44.40 45.90 16.87   0.48 
Butanoic Acid 1179 8.43 19.49 11.93 66.34 18.80 19.61   0.25 
2,6-Dimethyl-6-
trifluoroacetoxyoctane 1109 2.72 0.56 5.74 4.90 3.97 1.73   0.27 
Bishenol A 2220 2.55 26.60 24.72 18.42 8.66 9.51   0.34 
Tetracosanoic Acid 2724 16.46 6.65 47.05 38.54 25.60 13.90   0.27 
N-Acetyl-D-glucosamine 2117 0.00 75.28 100.48 89.95 50.41 46.65   0.58 
 
40  
TABLE 9. Identified metabolites in AOM + DSS mice, supplement 
Metabolites LRI2 Diet Treatment – AOM + DSS  
AIN-93G1 2.5% 1:11 2.5% 20:11 10% 1:11 10% 20:11 SEM p-value 
Pryidine 1151   8.61 14.16 5.90 16.38 12.57 4.22 0.42 
3-Pyridinecarboxylic acid 1285 40.33 25.80 40.10 27.37 17.20 11.30 0.55 
4,4’-Bipyridine 1530 28.82 38.99 17.74 35.85 37.28 10.99 0.64 
Propanoic Acid 1099 1137.80 558.81 1170.78 379.87 177.09 424.76 0.37 
Acetic Acid 1107 72.24 53.30 51.53 56.05 52.65 15.24 0.86 
L-Valine 1115 1189.16 1133.25 1153.76 1022.51 684.20 271.56 0.68 
L-Alanine 1546 171.55 172.88 118.48 129.12 99.95 32.35 0.42 
5-oxo-L-Proline 1527 280.78 185.78 303.37 250.02 262.59 56.21 0.65 
L-Proline 1293 148.56 136.20 181.68 135.84 77.15 42.27 0.54 
L-Glycine 1136 982.96 939.25 951.21 880.70 687.54 147.19 0.64 
L-Leucine 1162 1105.56 1025.89 1074.16 874.79 605.92 239.17 0.58 
L-Serine 1254 697.37 662.20 665.33 595.41 422.59 142.57 0.67 
L-Methionine 1404 156.31 158.78 122.92 118.82 104.74 31.46 0.68 
L-Aspartic Acid 1422 927.79 603.09 920.31 432.23 366.23 265.86 0.43 
L-Glutamic Acid 1635 546.26 533.56 646.09 392.80 312.17 142.71 0.50 
L-Phenylalanine 1638 367.92 274.91 434.64 155.17 172.75 109.74 0.33 
L-Tryptophane 2196 100.51 94.33 83.58 84.76 55.82 25.15 0.76 
L-Tyrosine 1890 650.78 720.67 677.31 612.47 435.21 179.67 0.82 
L-Theronine 1291 756.58 616.85 449.81 634.22 478.25 149.33 0.60 
d-Ribose 1713 806.11 655.68 772.45 612.01 430.36 211.91 0.74 
D-(-)-Rhamnose 1759 149.58 124.71 108.92 139.46 86.07 43.87 0.86 
d-Glucose 1934 1047.18 1471.33 1562.71 1494.32 856.32 383.12 0.62 
Mannose 2018 158.95 120.28 130.24 258.63 103.51 71.68 0.57 
Glycerol 1274 402.88 317.42 482.81 279.52 218.11 97.63 0.36 
1-O-Octadecylglycerol 2612 103.96 92.56 52.56 54.84 48.03 28.07 0.51 
Dimethylketene 1179 150.25 154.95 126.22 131.29 91.72 32.37 0.67 
Dodecamethyl-
Pentasiloxane 1182 16.43 16.40 13.16 27.50 14.51 7.78 0.71 
Urea 1231 138.89 135.65 125.36 128.95 112.43 24.04 0.94 
Phosphoric acid 1272 6.59 4.93 9.82 9.48 5.65 2.30 0.45 
Dopamine 1358 103.64 55.76 118.79 72.96 85.80 27.24 0.52 
Pryimidine 1335 197.41 158.81 248.99 132.30 107.29 57.31 0.45 
Benzoic Acid 1522 2.84 10.66 4.09 5.62 9.50 2.82 0.25 
Benzeneacetic Acid 1647 476.56 235.05 322.64 331.83 366.15 125.05 0.75 
Dodecanoic Acid 1655 77.37 76.47 78.82 49.63 44.49 15.22 0.33 
Benzenepropanoic Acid 1736 20.73 39.02 33.04 16.43 43.73 12.66 0.50 
2-Pyrrolidone-5-
carboxylic Acid 1536 304.14 316.92 236.75 223.58 207.93 54.57 0.53 
9H-Purine 1815 116.78 89.71 112.48 60.37 58.66 31.49 0.55 
Linoleic Acid 2205 383.26 130.07 130.43 191.20 126.07 77.79 0.12 
Deoxycholic Acid 3058 228.45 156.81 95.40 173.35 219.22 79.86 0.77 
Benzene 1250 3.08 6.09 1.82 5.82 3.55 1.39 0.17 
Butanedioic Acid 1307 51.59 33.86 39.83 25.70 23.45 14.41 0.65 
Tetradecanoic Acid 1849 24.26 20.82 21.35 16.23 10.51 8.50 0.81 
5-Methyl-Pyrimidine 1401 13.81 5.63 11.79 4.01 4.94 2.97 0.094 
Adenine 1873 31.41 24.46 34.25 32.66 16.88 10.85 0.78 
11-Eicosenoic acid 2388 203.93 111.23 98.49 73.32 37.88 48.12 0.19 
Pentadecanoic Acid 1915 39.68 13.51 37.04 25.62 12.38 10.99 0.28 
2,6-Dimethyl-6-
trifluoroacetoxyoctane 1109 3.36 5.83 2.23 5.09 4.65 1.63 0.55 
Bisphenol A 2220 6.26 1.24 10.47 22.39 7.12 7.01 0.30 
N-Acetyl-D-glucosamine 2117 198.46 289.27 156.06 268.41 185.61 91.52 0.82 
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TABLE 10. Unknown metabolites in sham mice, supplement 
Unknown 
Metabolites 
LRI Diet Treatment - Sham 
AIN-93G 2.5% 1:1 2.5% 20:1 10% 1:1 10% 20:1 SEM p-value 
Unknown 1 1076   23.44    21.26      48.95   33.85     34.81 15.14    0.71 
Unknown 2 1097    1.871 2.311 4.390 5.667 6.486 1.36    0.10 
Unknown 3 1397  393.89 930.66   996.49 1578.34 928.15 386.07    0.34 
Unknown 4 1590 7.148 8.227 0.821 16.506 28.759 9.88    0.34 
Unknown 5 1480 0.000 10.921 2.110 10.683 14.531 6.04    0.39 
Unknown 6 1290 0.000 165.369 72.628 206.189 148.831 0.98    0.44 
Unknown 7 2431 8.290 40.041 66.045 41.838 61.475 20.58    0.32 
Unknown 8 2068 2.972 28.433 48.103 24.311 30.292 14.93    0.35 
Unknown 9 1265 0.723 9.370 5.300 10.184 12.304 4.20    0.34 
Unknown 10 1318 4.250 15.756 6.581 11.446 25.139 6.24    0.17 
Unknown 11 1862 17.987 71.277 67.828 87.146 157.946 41.66    0.24 
Unknown 12 2440 5.773 38.098 68.618 49.440 106.108 29.24    0.20 
Unknown 13 3188  363.69  1141.82  1222.37 1122.74 1376.75 360.00    0.34 
Unkno wn 
14 1122 0.391 0.074 1.014 0.732 0.915 0.39    0.44 
Unknown 15 2197     9.61   12.71     14.80   21.64       6.56 6.62    0.57 
Unknown 16 1156 2.437 1.740 11.405 3.889 9.980 2.96 0.088 
Unknown 17 1212 2.945 5.129 9.268 7.688 13.284 2.68 0.099 
Unknown 18 1957 1.851 6.929 5.806 6.754 2.863 2.24    0.38 
Unknown 19 3294 1.553 18.566 2.092 6.896 7.937 7.02    0.45 
Unknown 20 2021 0.335 4.729 5.119 2.791 0.883 1.70    0.20 
Unknown 21 1291 2.512 0.823 2.490 3.147 0.475 1.65    0.73 
Unknown 22 1682 1.363 1.726 0.000 2.550 0.163 1.08    0.43 
Unknown 23 1086 0.360 1.164 1.189 1.709 1.819 0.92    0.81 
Unknown 24 1754 0.000 1.054 0.432 5.220 0.000 1.69    0.18 
Unknown 25 2264 0.437 2.082 2.740 5.674 0.000 2.97    0.68 
Unknown 26 2955 26.769 0.000 10.357 24.429 34.999 16.37    0.58 
Unknown 27 1938 386.033 975.765 911.513 1369.803 976.799 337.85    0.39 
Unknown 28 2757 3.797 25.762 3.484 62.893 39.056 15.56 0.060 
Unknown 29 2946 24.874 74.452 88.096 75.859 96.177 28.98    0.47 
Unknown 30 2956 211.826 1324.562 733.643 1349.029 1265.731 417.17    0.26 
Unknown 31 3047 137.191 419.843 351.234 397.996 524.824 135.55    0.37 
Unknown 32 3085 153.549 807.565 574.533 916.394 1258.524 282.12    0.11 
Unknown 33 1120 1.002 1.030 2.575 2.963 1.743 0.86    0.39 
Unknown 34 2847 12.269 0.000 1.255 7.139 10.946 7.04    0.65 
Unknown 35 3027 34.551 18.020 23.652 168.923 30.306 40.43 0.068 
Unknown 36 1085 16.974 15.134 36.200 29.457 26.175 12.98    0.77 
Unknown 37 1291 105.250 176.283 225.995 280.843 231.154 95.28    0.75 
Unknown 38 1525 36.014 102.687 77.976 195.757 81.698 47.11    0.21 
Unknown 39 1153 47.239 73.101 111.144 101.895 212.797 40.68 0.076 
Unknown 40 2140 8.396 26.934 17.387 22.417 12.328 8.03 0.50 
Unknown 41 1340 0.000 3.896 2.398 6.019 1.574 1.54 0.096 
Unknown 42 2141 5.030 23.254 29.967 8.592 8.229 8.39 0.18 
1 Values are expressed as mean ratio 
2 Linear retention index 
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TABLE 11. Unknown metabolites in AOM + DSS mice, supplement 
Unknown 
Metabolites 
LRI Diet Treatment – AOM + DSS   
 AIN-93G 2.5% 1:1 2.5% 20:1 10% 1:1 10% 20:1 SEM p-value 
Unknown 1 1076    39.83    39.64     27.12    44.97      37.36 11.24   0.85 
Unknown 2 1097 2.573 2.564 1.069 2.117 2.231 1.04   0.84 
Unknown 3 1397  1187.67 1158.03 1266.26  934.43    621.56 283.86   0.51 
Unknown 4 1590 19.732 10.685 21.717 15.414 15.023 6.19   0.74 
Unknown 5 1480 10.163 3.889 5.724 9.911 4.252 3.27   0.50 
Unknown 6 1290 226.094 127.161 165.739 136.101 93.433 71.15   0.74 
Unknown 7 2431 47.203 16.214 24.927 24.489 16.257 11.61   0.34 
Unknown 8 2068 9.245 23.092 27.224 19.088 1.963 8.87   0.28 
Unknown 9 1265 17.321 14.085 15.339 14.499 9.166 4.10   0.71 
Unknown 10 1318 8.706 3.473 8.588 5.046 9.699 3.20   0.60 
Unknown 11 1862 85.990 70.304 73.301 71.508 46.442 21.04   0.76 
Unknown 12 2440 25.611 15.277 0.000 2.487 7.032 7.36   0.12 
Unknown 13 3188  1063.52 820.39   607.22 661.13   565.00 240.75   0.59 
Unknown 14 1122 0.832 0.875 0.000 1.395 0.615 0.38   0.16 
Unknown 15 2197 0.623 2.874 0.379 3.706 0.531 0.97    0.064 
Unknown 16 1156 3.976 4.578 1.116 3.765 4.613 1.99   0.72 
Unknown 17 1212 6.504 7.745 5.348 4.675 6.186 1.60   0.71 
Unknown 18 1639 25.70   41.04     66.50    23.57 14.05 15.97   0.19 
Unknown 19 1957 5.335 8.011 6.178 5.950 5.643 2.01   0.89 
Unknown 20 3294 27.401 19.796 15.550 11.940 5.087 7.66   0.34 
Unknown 21 2021 4.647 4.045 3.970 3.249 3.654 1.80   0.99 
Unknown 22 1291 17.506 4.536 8.001 5.169 5.456 3.78   0.12 
Unknown 23 1682 6.629 6.677 11.264 2.817 2.796 3.18   0.33 
Unknown 24 1086 2.670 1.044 1.064 1.021 0.599 0.57   0.12 
Unknown 25 1754 9.485 3.189 1.355 0.692 4.365 2.40   0.11 
Unknown 26 2955 0.000 0.000     233.149 51.833 0.000 106.81   0.48 
Unknown 27 1938  1284.165 1094.035 1047.349 772.773 627.285 246.70   0.36 
Unknown 28 2757      77.180 42.290 27.878 22.854 15.605    18.8   0.19 
Unknown 29 2946 80.961 48.861 38.113 51.502 29.577 24.20   0.63 
Unknown 30 2956 1483.341 1664.687 883.719 860.346 502.774 337.34   0.12 
Unknown 31 3047 551.642 442.625 271.904 248.834 185.416 135.33   0.31 
Unknown 32 3085 715.068 474.951 671.448 710.646 316.965 236.55   0.70 
Unknown 33 1120 2.145 2.650 1.399 1.847 1.918 0.64     0.73 
Unknown 34 1291 194.725 110.196 17.974 89.353 142.167 42.68  0.082 
Unknown 35 1525 154.288 136.587 152.514 112.901 67.969 46.22   0.66 
Unknown 36 1153 99.561 96.206 102.089 95.833 89.155 23.33   0.10 
Unknown 37 2831 0.000 0.000 0.000 0.000 0.273 0.12   0.43 
Unknown 38 2140 21.949 22.331 13.344 10.337 12.062 4.75   0.25 
Unknown 39 1340 1.322 2.271 5.187 5.009 4.179 2.45   0.74 
Unknown 40 2141 17.582 2.825 9.765 0.000 1.096 5.26   0.13 
1 Values are expressed as mean ratio 
2 Linear retention index 
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CHAPTER 3 
THE DEVELOPMENT OF THE TOTAL WESTERN DIET-2 
 
Abstract 
 Rodents are commonly used as models for studying various human diseases. Typically 
these animals are fed a standardized diet developed to optimize growth, however when comparing 
these diets to what the average American consumes, their nutrient densities are very different. 
Because diet is known to impact gut health and disease, Hintze and colleagues developed the 
Total Western Diet (TWD).  By using data collected from the NHANES survey and translating it 
to a rodent diet using a nutrient density approach, they were able to create a standardized rodent 
diet that matches both the macro- and micronutrient content of the average American diet.  
However, the complex dietary components of whole-foods, like dietary fiber, can also impact gut 
health, so the TWD was redesigned to incorporate the use of whole foods in the formulation.  
Using the original TWD formulation and the USDA Food Commodities Database, the TWD-2 
incorporates whole-foods while matching both the macro- and micronutrient content of the 
average American diet. The TWD-2 will help replicate the complex relationship between the gut 
microbiome and the human digestive system in rodents.  Use of this diet can more accurately 
emulate the complexities of the human digestive system making the rodent a better model for 
human disease research. 
 
Introduction 
 The influence of diet composition and the resulting gut microbiome is a relatively new 
area of research and is growing rapidly.  Studies have demonstrated that diet has a major impact 
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on the gut microbiome of the host.  In addition, a strong link between gut microbiome 
composition and colon health has been established (26-28). This strong relationship between diet, 
gut microbiome, and colon health points to a potential issue in results generated from studies 
using the current rodent diets to research colon diseases.  When comparing the AIN rodent diets 
to the typical Western diet consumed by people in most developed nations there are several 
meaningful differences in the nutrient composition.  Currently, the only rodent diet developed 
that accurately matches the nutrient composition of the average American diet is the Total 
Western Diet (TWD) (4). Unlike the AIN diets, the TWD gave researchers a formulated diet that 
replicated Western intakes. The compositional differences between the AIN and TWD diets 
suggest that the AIN developed diets may potentially skew research results when investigating 
interactions between diet and chronic disease.  For example when comparing fiber levels, the 
TWD contains approximately half the amount of dietary fiber found in the AIN-93G diet. The 
research literature pertaining to dietary fiber and colorectal cancer suggests there is an inverse 
relationship between these two factors (31, 67).  Individuals that consume diets rich in refined- 
gains had roughly a 40% increased risk of rectal cancer; where as individuals who consumed 
more whole-grains reduced their risk of rectal cancer by approximately 30% (67). Enzymes 
produced by bacteria in the colon are able to cleave the undigested insoluble fiber and release 
bioactive plant metabolites. These plant metabolites are able to turn on endogenous antioxidant 
genes which have been shown to protect DNA from oxidative damage through the sequestering of 
reactive oxygen species (32). Along with the dietary fiber content, the fatty acid profile of the 
AIN diets and the TWD are vastly different. This variation is significant as some studies have 
examined the effects of dietary fat intake on colon cancer and found that not only do the type of 
fatty acids effect cancer incidence, but the composition of fatty acids within the diet can impact 
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colorectal cancer occurrence as well (68, 69). Studies have also shown an inverse relationship 
between calcium and vitamin D intakes and CRC occurrence (70, 71). This is a quite relevant as 
there is more than twice the amount of calcium and almost three times more vitamin D in the 
AIN-93G than the TWD (Table 2). 
 Unlike the typical human diet, which is composed of diverse and highly complex foods, 
the AIN and TWD diets were developed using purified ingredients including: cornstarch, casein, 
sucrose. Additionally, cellulose is used as the single source of fiber (4, 72). With this type of diet 
formulation the majority of the nutrients are absorbed in the small intestine. By limiting the 
amount of nutrients that reach the large intestine, the gut microbiota composition will 
consequently reflect this lack of fermentable substrates.  Previous research has shown this lack of 
complexity found in the AIN diets could potentially have a major impact on the gut microbiome 
of the test subjects and could therefore obscure research results when investigating the role of the 
Western dietary pattern in the development of colorectal cancer in humans (4). 
In a study investigating how dietary factors affect the gut microbiota of individuals, the 
microbiome of two different diet groups, a Western Diet and a rural, well-balanced diet, were 
compared.  Results from this study found a complete separation of the hierarchical clustering of 
bacteria between these two diet groups.  In addition, the microbiome of the rural, well-balanced 
diet had a higher microbial richness and diversity (29). These results are important, as intestinal 
inflammation is believed to be associated with a decrease in amount and complexity of bacteria in 
the gut (73). Research has shown approximately 60% of the gut microbiota diversity is directly 
associated with an individuals diet and only 10% correlated to genetics (26). The dietary 
components that are not completely digested and absorbed in the upper digestive tract are a 
source of energy for the gut microbiota found in the colon (26).  Short-chain fatty acids (SCFA) 
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including acetate, butyrate, and propionate are produced by bacteria as a byproduct of 
fermentation (31). The presence of butyrate and butyrate-producing bacteria has been shown to 
have a protective affect against CRC (33). 
To better understand the correlations between the Western diet and human chronic 
disease, a different dietary model is needed to better replicate the actual human digestive 
experience when using rodent models. For that reason, a whole-food based rodent diet that 
emulates American dietary patterns was created, called the Total Western Diet 2 (TWD-2).  Like 
the TWD, the TWD-2 was formulated using the average daily intake of all macro- and 
micronutrients reported by NHANES (25). Then, using the USDA commodity database, whole 
foods were selected that contributed more than 0.1% of the daily calories for the average 
American (43). Therefore, by using whole-food ingredients the TWD-2 matches the macro- and 
micronutrient composition of an average American diet. Through the use of whole-foods in the 
formulation, the TWD-2 will not only better emulate American eating patterns, but it will also 
allow the dietary components of whole-foods, like whole-grains, natural antioxidants, and the full 
portfolio of dietary fiber sources to influence the gut microbiota of rodents models.  The TWD-2 
will give researchers a diet that emulates all aspects of American dietary patterns. Use of this diet 
should make the rodent a better model for human chronic disease research.  
 
Methods 
 
Diet Formulation 
 The TWD formulation developed by Hintze et al., used the NHANES survey What We 
Eat in America for the years 2007-2008 and translated the average American’s daily intake to a 
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rodent diet using a nutrient density approach (4, 25). The same methodology was used in the 
development of the TWD-2.  The base diet was formulated to match the average American’s 
macronutrient intakes reported by NHANES, which included 543.2 g/kg of carbohydrates, 167.8 
g/kg of protein, and 165.4 g/kg of fat on a dry matter basis. Using the USDA Retail Food 
Commodities, food ingredients were added to the diet based on the percentage of calories they 
contributed to the American diet (43).   Ingredients were classified as either carbohydrate or 
protein foods and added to the formulation to achieve 543.2 g/kg or 167.8 g/kg, respectively.  For 
instance, according to the NHANES survey, sugar accounts for 36.4% of carbohydrate calories, 
so 543.2 g/kg total carbohydrates x 0.364 = 198 g/kg. Thus, approximately 198 g/kg of sugar was 
used in the formulation. All carbohydrate and protein food commodities were added to the diet 
using this methodology.  Dairy foods contributed sources of both carbohydrates and proteins, so a 
combination of whey, casein, and lactose were used.  Lean cuts of meat were used as protein 
ingredients to minimize the initial fat content.  Lastly, to achieve a total fat content of 165.4 g/kg 
diet, initial fat content of the carbohydrate and protein ingredients were analyzed by GC and the 
fatty acid profile of the diet was matched to the NHANES data by adding a diverse blend of oils 
(Tables 12-14).  Micronutrient analysis was done on a pilot batch of the TWD-2 to identify any 
vitamin or mineral deficiencies or excesses.  A supplement was purchased and added to the diet, 
which ensured a micronutrient match of the average American diet. 
 
Product Development 
 Ingredients selected from the Retail Food Commodity Intake database were purchased 
and prepared in Utah State University’s Sensory Laboratory.  
 
  
Table 12.  Macronutrient profile of the Total Western Diet 2     
Carbohydrate Foods Ingredients % Carbohydrate of US Diet 
% Protein 
of US Diet 
g/kg Carbohydrate 
in TWD-2 
g/kg Protein 
in TWD-2 
Estimated g/kg 
Fat in TWD-2  
Total Amount 
of Ingredient (g) 
Caloric Sweeteners 50% sugar 50% HFCS 36.4   0.0 204.3     0.0    0.0  242.0 
Wheat Wheat Flour 24.4 10.5 136.9   18.5    0.9  179.5 
Potatoes Potato Flour   6.9   1.9   38.6     3.2    0.08    46.4 
Orange juice Freeze dried Orange juice   6.8   1.5  38.3     2.6    0.4     43.1 
Dairy Carb. Lactose   6.3   0.0  35.1     0.0    0.0     35.1 
Corn Corn flour   5.2   1.4  29.3     3.6    0.8     38.4 
Rice  Rice flour   3.3   0.8  18.3     1.4    0.2     22.9 
Bananas Freeze dried banana   2.0   0.0  11.3     0.0    0.1     12.8 
Legumes Dry roasted soybeans   1.7   1.9   9.5   11.5    3.3     29.2 
Grapes Freeze dried grapes   1.5   0.0   8.2     0.0    0.08       8.8 
Apple juice Freeze dried apple juice   1.3   0.0   7.3     0.0    0.04       7.6 
Oat Oat flour   1.1   0.8   6.2     1.4    0.4       9.5 
Snap beans Freeze dried canned beans   1.1   2.0   6.2     1.9    0.3     10.3 
Apple Freeze dried apple slices   0.9   0.0   5.3     0.0    0.04       5.5 
Berries Freeze dried strawberries   0.3   0.0   1.5     0.0    0.03       1.7 
Protein Foods        
Dairy Protein Casein   0.0 22.0   0.0   42.4    0.0     42.4 
Beef Freeze dried cooked ground beef   0.0 17.4   0.0   33.6    0.0     43.3 
Chicken/turkey 
Freeze dried cooked chicken 
tenders   0.0 18.5   0.0   35.6    4.1     44.6 
Pork Freeze dried cooked ground pork   0.0   9.9   0.0   19.1    4.7     24.4 
Eggs Dried egg whites   0.0  5.5   0.0   10.6    2.3     13.1 
Fish Freeze dried baked catfish   0.0  4.1   0.0     6.4    2.5       8.9 
Peanuts Roasted peanuts no salt   0.4  1.3   2.2     2.6    0.5      10.4 
Tree nuts Roasted cashews no salt   0.3  0.4   1.6     0.7    2.7       4.8 
Fats        
Olive Oil    0.0  0.0   0.0     0.0  23.7     23.7 
Soybean Oil    0.0  0.0   0.0     0.0  26.5     26.5 
Corn Oil    0.0  0.0   0.0     0.0  13.9     13.9 
Lard    0.0  0.0   0.0     0.0  23.7     23.7 
Beef Tallow    0.0  0.0   0.0     0.0  21.0     21.0 
Anhydrous Milk Fat    0.0  0.0   0.0     0.0  30.7     30.7 
Cholesterol    0.0  0.0   0.0     0.0    0.3       0.3 
   Totals             560.1 195.1 163.3 1024.5 
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 Table 13. Mineral profile of the Total Western Diet 2          
Carbohydrate Foods Ingredients Fiber (g) Ca P Na K Mg Fe Zn Cu Se 
Caloric sweeteners 50% sugar 50% HFCS   0.0     0.0       0.0     0.0       0.0     0.0   0.0   0.0 0.0 0.0 
Wheat Wheat Flour   4.8   27.0   194.0     4.0   192.0   39.0   2.1   1.3 0.0   0.06 
Potatoes Potato Flour   2.7   30.0     78.0    26.0   465.0   30.0   0.6   0.3 0.0 0.0 
Orange juice Freeze dried Orange juice   0.7   41.0     63.0     4.0   737.0   41.0   0.7   0.2 0.0 0.0 
Dairy Carb. Lactose   0.0     0.0       0.0     0.0       0.0     0.0   0.0   0.0 0.0 0.0 
Corn Corn flour   2.5   52.0     82.0     2.0   101.0   36.0   0.6   0.7 0.0   0.01 
Rice Rice flour   0.5     2.0     22.0     0.0     17.0     8.0   0.08   0.2 0.0 0.0 
Bananas Freeze dried banana   1.3     3.0       9.0     0.0   191.0   14.0   0.2   0.1 0.0 0.0 
Legumes Dry roasted soybeans   2.4   41.0   189.0     1.0   398.0   66.0   1.2   1.4 0.0   0.01 
Grapes Freeze dried grapes   0.4     7.0       5.0     1.0     89.0     2.0   0.1   0.02 0.0 0.0 
Apple juice Freeze dried apple juice   0.1     5.0       5.0     3.0     65.0     3.0   0.08   0.01   0.01 0.0 
Oat Oat flour   0.6     5.0     43.0     2.0     35.0   14.0   0.4   0.3   0.04 0.0 
Snap beans Freeze dried canned beans   3.7   56.0     31.0 360.0   155.0   19.0   1.29   0.3   0.06 0.0 
Apple Freeze dried apple slices   0.9     2.0       4.0     0.0     41.0     2.0   0.05   0.02   0.01 0.0 
Berries Freeze dried strawberries   0.4     3.0      5.0     0.0     29.0     2.0   0.08   0.03   0.01 0.0 
Protein Foods            
Dairy Protein Casein   0.0     0.0       0.0     0.0       0.0     0.0   0.0   0.0 0.0 0.0 
Beef Freeze dried cooked ground beef   0.0   10.0   245.0   71.0   387.0   27.0   3.8   8.4 0.1   0.03 
Chicken/turkey Freeze dried cooked chicken tenders   0.0   18.0   240.0 106.0   299.0   31.0   1.5   2.6   0.08   0.03 
Pork Freeze dried cooked ground pork   0.0   12.0   163.0   52.0   268.0   17.0   0.7   1.6   0.03   0.03 
Eggs Dried egg whites   0.0     8.0     15.0 167.0   147.0   12.0   0.02   0.01   0.02   0.02 
Fish Freeze dried baked catfish   0.0     3.0     86.0   41.0   127.0     8.0   0.1   0.2 0.0   0.05 
Peanuts Roasted peanuts no salt   0.8     6.0     37.0     1.0     68.0   18.0   0.2   0.3   0.07 0.0 
Tree nuts Roasted cashews no salt   0.1     2.0     23.0     1.0     27.0   12.0   0.3   0.3 0.1 0.0 
 Totals 21.9 333.0 1539.0 842.0 3838.0 401.0 14.1 18.3 0.5 0.2 
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 Table 14. Vitamin profile of the Total Western Diet 2           
Carbohydrate 
Foods Ingredients Thiamin Riboflavin Niacin B6 Folate B12 A (IU) D (IU) E (IU) K Choline Cholesterol 
Caloric sweeteners 50% sugar 50% HFCS 0.00 0.00  0.00 0.00 0.00   0.00        0.00     0.00 0.00    0.00     0.00       0.00 
Wheat Wheat Flour 0.22   0.072  2.24 0.00   0.047   0.00        0.00     0.00 0.11 0.005 18.7       0.00 
Potatoes Potato Flour 0.11   0.024  1.63 0.00   0.012   0.00        0.00     0.00 0.12    0.00     18.3       0.00 
Orange juice Orange juice 0.33 0.11  1.47 0.00 0.11   0.00  737.0     0.00 0.15   0.0004     22.8       0.00 
Dairy Carb Lactose 0.00 0.00  0.00 0.00 0.00   0.00        0.00     0.00 0.00    0.00    0.00       0.00 
Corn Corn flour   0.086   0.037  0.63 0.00   0.011   0.00        2.00     0.00 0.05    0.00    3.3       0.00 
Rice  Rice flour   0.032   0.005  0.59 0.00 
  
0.0001   0.00        0.00     0.00 0.03    0.00    1.3       0.00 
Bananas Freeze dried banana   0.023   0.031  0.36 0.00   0.002   0.00     32.0     0.00 0.05   0.0003    2.5       0.00 
Legumes Dry roasted soybeans 0.12  0.22  0.31 0.00 0.06   0.00        0.00     0.00 0.00 0.011      0.00       0.00 
Grapes Freeze dried grapes   0.043    0.027  0.14 0.00   0.002   0.00     47.0     0.00 0.09   0.0068    2.6       0.00 
Apple juice Apple juice   0.014    0.011    0.047 0.00 0.00   0.00        1.00     0.00 0.01    0.00    1.2       0.00 
Oat Oat flour   0.066    0.012  0.14 0.00   0.003   0.00        0.00     0.00 0.07   0.0003    2.8       0.00 
Snap beans 
Freeze dried canned 
beans   0.023    0.066     0.3 0.00   0.041   0.00  517.0     0.00 0.04 0.057  21.5       0.00 
Apple 
Freeze dried apple 
slices   0.007   0.01    0.035 0.00   0.001   0.00     21.0     0.00 0.00   0.0008    1.3       0.00 
Berries 
Freeze dried 
strawberries   0.005   0.004   0.074 0.00   0.005   0.00        2.00     0.00 0.08   0.0004    1.1       0.00 
Protein Foods 
             
Dairy Protein Casein & Whey 0.00 0.00   0.00 0.00 0.00   0.00        0.00     0.00 0.00    0.00     0.00       0.00 
Beef 
Freeze dried cooked 
ground beef   0.042 0.21   6.80 0.44   0.007 0.0031        0.00     0.00 0.47   0.0016   110.7   90.0 
Chicken/turkey 
Freeze dried cooked 
chicken tenders   0.085 0.22  11.29 0.58   0.007 0.0004     65.0     6.00     0.0003 0.003  97.0 110.0 
Pork 
Freeze dried cooked 
pork 0.31 0.30   6.91  0.45 0.00 0.0005        0.00     0.00     0.00018    0.00  62.1   49.0 
Eggs Dried egg whites   0.001 0.33   0.11 0.005   0.002   0.00        0.00     0.00 0.00    0.00    1.1       0.00 
Fish 
Freeze dried baked 
catfish   0.008   0.035   0.88  0.065   0.004   0.0012        0.00     4.00 0.34   0.0009     0.00   23.0 
Peanuts 
Roasted peanuts no 
salt   0.045 0.01  1.4  0.027   0.015   0.00        0.00     0.00     0.00072    0.00    5.7       0.00 
Tree nuts 
Roasted cashews no 
salt 0.01 0.01    0.067  0.012   0.003   0.00        0.00     0.00 0.04   0.0017    2.9       0.00 
 Totals 1.58 1.75 35.42 1.58 0.33 0.0052 1424.0 10.0 1.65 0.089 376.9 272.0 
50 
51 
 
The leanest meats were selected to limit added fat. Meats were cooked in aluminum pans without 
additional oil and catfish was baked according to the manufactures direction Produce and meats 
were thinly sliced, frozen at-80°C overnight, and then freeze-dried at -80°C in a vacuum freeze-
dryer.  After freeze-drying, products were processed in a food processor and vacuum sealed in 
individual bags.  Freeze-dried ingredients, added oils, juices, and other dry ingredients including 
a micronutrient supplement (see Table 17), were added according to the TWD-2 formulation 
(Table 12). After all ingredients were thoroughly mixed, the complete diet was freeze-dried again 
to obtain a water activity (aw) of approximately 0.50, which is similar to a commercial rodent diet. 
 
TWD-2 Fat Analysis - FAMES 
 To determine the initial fatty acid profile of the TWD-2, the diet was analyzed using 
direct fatty acid methyl ester (FAME) synthesis according to O’Fallon et al. and samples were 
analyzed using a GC2010 (Shimadzu) instrument (59). A 1 µL sample was injected into the gas 
chromatograph at a 150:1 split ratio with an inlet temperature held at 250°C. The temperature 
program started at 153°C for 2 min, followed by a 2.3°C/min-ramp to 174°C, with a hold time of 
20 sec. A second temperature increase was performed with a 2.5°C/min-ramp to a final 
temperature of 210°C, which was then held for 5 min. Separation was performed on a DB-23 
column (30 m length, 0.25 mm diameter and 0.25 µm film thickness) using helium as the carrier 
gas. 
 
TWD-2 Fat Analysis - Soxhlet 
 Soxhlet extraction was carried out according to Mariod et al. with slight modifications 
(74).  The TWD-2 was homogenized, placed into cellulose thimbles and soaked in petroleum 
52 
 
ether overnight.  Fatty acid extraction was done with petroleum ether in a Soxhlet apparatus for 6 
hours.  Fat was recovered using a rotary evaporator and any remaining solvent was removed 
using 99.9% nitrogen. 
 
TWD-2 Micronutrient Analysis   
 To determine the micronutrient content of the TWD-2, a pilot batch was sent to 
Medallion Laboratories (Plymouth, MN) for vitamin analysis.  USU analytical labs performed the 
mineral analysis.  From these analyses, a micronutrient supplement was formulated to ensure the 
TWD-2 matched the micronutrient composition of the average American diet. 
 
Results 
 
Initial Fat Content of TWD-2  
 The fat content of the selected carbohydrate and protein food commodities was analyzed 
via gas chromatography (Table 15).  As expected from the diet formulation, an initial fat content 
of approximately 2% was calculated. The Soxhlet extraction confirmed these results (data not 
shown). Taking into account the 2% fat measured in the carbohydrate and protein food 
commodities, we were able to determine the amount and type of dietary fat needed using the 
same percentages from the oil blend used in the TWD formulation  (Table 16). 
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TABLE 15. Initial fat analysis of TWD-2 via gas chromatography  
Fatty Acid TWD-2 (g/kg) Standard Error 
1.573 0.01  4.2E-4 
C8:0 0.01 2.3E-4 
C10:0 0.01 8.4E-4 
C12:0 0.02 2.2E-3 
C14:0 0.24 2.6E-2 
C14:1c-9 0.04 5.1E-3 
5.49 0.01 5.7E-4 
5.71 0.01 1.3E-3 
C15:0 0.04 3.7E-3 
C16:0 4.06 2.6E-1 
C16:1t-9 0.03 2.8E-3 
C16:1c-9 0.35 3.7E-2 
C17:0 0.10 9.1E-3 
C17:1ca  0.50 1.1E-2 
C18:0 1.88 1.3E-1 
C18:1T 0.16 1.3E-2 
C18:1n-9 8.74 2.5E-2 
C18:1n-7 0.35 2.6E-2 
C18:2n-6 4.28 1.2E-1 
C20:0 0.09 7.0E-3 
C18:3n-3 0.34 3.1E-3 
C20:1n-12 0.01 2.6E-3 
C20:1n-9 0.11 5.6E-3 
C20:2n-6 0.04 4.2E-3 
C22:0 0.10 1.6E-2 
C20:3n-6 0.05 3.4E-3 
C20:4n-6 0.21 1.3E-2 
C20:5n-3 0.02 2.9E-3 
C22:4n-6 0.06 5.1E-3 
C22:3n-3 0.02 4.4E-4 
C22:5n-3 0.03 2.4E-3 
C24:0 0.06 8.8E-3 
C22:6n-3 0.11 4.8E-3 
Total Fat 22.08  
 a Internal standard 
 
TWD-2 Micronutrient Supplement   
 TWD-2 pilot batches were submitted for micronutrient analysis to determine the diet’s 
initial composition (Medallion Labs and USU analytical labs).  From these analyses a 
micronutrient supplement was developed and purchased (Harlan Teklad) (Table 17). Currently 
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there are three nutrients in the TWD-2 that exceed the average American consumption: niacin, 
vitamin D, and fiber.  Both niacin and vitamin D quantities are insignificantly higher but the total 
fiber is approximately 1.5 times greater than the target amount.  Analytical tests were not 
available for vitamin K and choline, so quantities were estimated through the use to the USDA 
nutrient database (75). 
 
TABLE 16. Oil blend formulation for TWD and TWD-2 
Oil Source % Oil TWD Formulation a TWD-2 Formulation a 
Olive Oil 16.9     28.0     23.7 
Soybean Oil 19.0     31.4     26.5 
Corn Oil 10.0    16.5     13.9 
Lard 16.9    28.0     23.7 
Beef Tallow 10.0    24.8     21.0 
Anhydrous Milk Fat 21.9    36.3     30.7 
Cholesterol  0.2     0.4      0.3 
Total Fat ~100 165.4 139.8 
      a Values are all listed as g/kg 
 
Discussion 
 The TWD-2 was successfully formulated and developed using whole-foods to match both 
the macro- and micronutrient intake of the average American diet.  Fiber quantities were the only 
nutrient to exceed the reported intake according to the NHANES survey (25). This is important, 
as studies have shown individuals who consume higher amounts of dietary fiber are at a 
decreased risk for developing CRC due to the phenolic compounds produced by bacteria breaking 
down undigested fiber (31, 67). While our fiber content exceeded the data reported by NHANES, 
there is a potential for the NHANES data to be skewed since it is self-reported.  In a redesign of 
the TWD-2, sources of fiber such as apple and grape skins could be removed in an effort to 
decrease the amount of fiber within the diet.   
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TABLE 17. Micronutrient analysis and supplement formulation 
Micronutrients TWD TWD-2 Micronutrient 
Supplement 
Minerals (mg/kg)    
  Ca 2011 900 1111 
  P 2757 2300 457 
  Na 7078 4241 2837 
  K 5333 4700 633 
  Mg 589 500 89 
  Fe 31 15.1 15.9 
  Zn 25 15.7 9.3 
  Cu 2.6 1.7 0.9 
  Se 0.2 0.0 0.2 
 Vitamins (unit/kg)    
  Thiamin-HCl (US) (mg) 3.5 2.2 1.30 
  Thiamin (EU) (mg) 3.5 1.73 1.77 
  Riboflavin (mg) 4.4 1.5 2.90 
  Niacin (mg) 50.6 53.4 0.00 
  Pryidoxine (mg) 3.9 3.09 0.81 
  Floate (mg) 1.3 0.82 0.48 
  B12 (mg) 0.011 0.008 0.003 
  A (IU)  4300 500 3800 
  D (IU) 391 400 0.00 
  E (IU) 24.6 15.8 8.80 
  K (mg) 0.189 0.089 0.10a 
  Choline (mg) 648 376.9 271.1a 
  Cholesterol (mg) 400 373 27 
Other    
  Fiberb (mg) 30000 49000 0.00 
a Quantities were estimated using the USDA nutrient database 
b This macronutrient was included in micronutrient analysis  
 
Incorporating whole-foods in the TWD, allows undigested dietary components like dietary fiber 
and other undigested dietary components to interact with the gut microbiota. Studies have shown 
SCFAs and bioactive plant metabolites produced from undigested dietary fiber have a protective 
effect against CRC.  Plant metabolites are able to turn on endogenous antioxidant genes which 
help to prevent cellular damage (32), while SCFA, specifically butyrate, is able to induce 
apoptosis and help prevent further tumor cell growth (33). The presence or absence of these 
metabolites can impact the individual’s colon health and could subsequently impact their risk for 
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CRC development. Metabolites produced through the breakdown of undigested food, are a major 
element missing from the purified diets developed by AIN.  From the published research we 
suspect the whole-food dietary component of the TWD-2 will impact the gut microbiome of 
rodents, making them a more accurate model for human CRC studies (26-28). 
 Freeze-drying of the individual food commodities was chosen as our method for 
controlling moisture content, since this method has been shown to be effective at preserving 
foods while maintaining the nutrient integrity (76). The target water activity of the TWD-2 was 
determined based on the water activity of the commercialized rodent diet, 0.50. Achieving a 
water activity of less than 0.6 prevents growth of molds, yeast, and pathogenic microorganisms 
(77). Another factor affecting microbial growth is pH level. To limit growth, pH levels should be 
below 4.6 to ensure pathogenic microorganisms are not present (77).  The TWD-2 should be 
stored at -4° C prior to feeding or -80° C if stored for extended periods of time. Storing the 
finished diet pellets at these temperatures will increase the products shelf life by preventing 
microbial growth, extraneous moisture absorption, and slowing or preventing fat oxidation (78). 
  Future work on the TWD-2 includes a comprehensive feeding study to examine the 
effects of the TWD-2, TWD, and AIN-93G on weight gain, the gut microbiome, systemic 
inflammation, and tumorigenesis in response to AOM + DSS.  We hypothesize that mice fed the 
TWD-2 or TWD diets will result in more tumorigenesis, due to its suboptimal micronutrient 
content. We also hypothesize the gut microbiome of mice fed the TWD-2 will be more reflective 
of the gut microbiome of the average American, and will be significantly different from the TWD 
and AIN-93G diets due to the use of whole-foods in the diet composition.
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CHAPTER 4 
SUMMARY 
 
Dietary PUFA and CRC 
 In response to published research and a preliminary study, we investigated whether a diet 
with a high PUFA concentration and a high n-6 to n-3 PUFA ratio would induce a larger 
tumorigenic response compared to a diet with a low PUFA concentration and low n-6 to n-3 
PUFA ratio, in response to AOM + DSS induced inflammation.   To determine CRC outcome, we 
measured tumor multiplicity, tumor size, colon length, systemic inflammation, fecal metabolites, 
and the fatty acid profiles of colon mucosa and red blood cell membranes.  From the experimental 
diets selected, we had hypothesized the diet with 10% energy from PUFA and an n-6 to n-3 ratio 
of 20:1 would result in an increased CRC response. From the measured endpoints, this 
hypothesized tumorigenic diet did not increase the CRC response in mice treated with AOM + 
DSS. However, our results did suggest that both the dietary PUFA content and the n-6 to n-3 ratio 
played a role in the development of CRC in response to AOM + DSS. The PUFA ratio played a 
more significant role in tumorigenesis, while the PUFA concentration played a more significant 
role in the systemic inflammatory response.  Although the published research suggests the 
Western diet, which is characterized by a high PUFA content and high n-6:n-3 ratio would 
promote CRC, the results from our study suggest diets with a high n-6:n-3 PUFA ratio have a 
protective effect against CRC in response to AOM + DSS induced inflammation.  It was also 
interesting to note that mice fed the control diet, AIN-93G, had elevated serum levels of pro- 
inflammatory cytokines, higher tumor multiplicity, and tended to have some of the largest tumors.  
These results from mice fed the AIN-93G diet, which contains approximately 7% energy from 
PUFA and an n-6 to n3 ratio of 7:1, suggest this intermediate level of PUFA content and n-6 to n-
3 ratio had a greater impact on CRC development than the other experimental diets in response to 
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AOM + DSS. This is interesting, as according to the NHANES survey What We Eat in America 
for the years 2011-2012, the average American consumes a diet that contains approximately 8% 
energy from PUFA and an n-6:n-3 ratio of approximately 10:1 (61). With components of the 
experimental diets used in this study having similarities to the average American diet, 
understanding how the PUFA concentration and n-6:n-3 play a role in the etiology of CRC is 
important.  Data from the other measured endpoints, systemic inflammatory response, fecal 
metabolomic analysis, and the fatty acid profiles of RBC and colon mucosal membranes, showed 
that the dietary PUFA content and/or n-6 to n-3 PUFA ratio influenced their respective outcomes. 
The dietary PUFA content greatly influenced the measured serum cytokine levels, while both the 
dietary PUFA content and n-6:n-3 PUFA ratio impacted the fecal metabolites produced and the 
fatty acid profiles of RBC and colon mucosal membranes.  In conclusion, we were able to 
determine a diet with a high PUFA concentration and high n-6:n-3 PUFA ratio does not induce a 
more tumorigenic response to AOM + DSS compared to our other treatments.  We found diets 
with a low n-6:n-3 PUFA ratio induced significantly larger tumors compared to diets with a high 
n-6:n-3 PUFA ratio. Moreover, mice fed the control AIN-93G diet, had an increased CRC 
outcome, compared to mice fed the other experimental diets. 
 
Development of the TWD-2  
 Diet has been shown to greatly influence the gut microbiome and subsequently colon 
health (26, 28, 29). Diets currently used in rodent studies, such as the AIN diets (21), are 
formulated using purified ingredients.  Because these rodent diets do not incorporate whole-foods 
into their formulations, they are missing the complex components like dietary fiber, bioactive 
plant metabolites, and SCFAs known to impact gut health (31-33, 67). Knowing the impact of 
whole-foods on gut health, it was evident that a new diet, which incorporates the use of whole 
foods in the formulation, needed to be developed.  To understand how the TWD-2 impacts the gut 
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microbiome and CRC, a mouse feeding study using the TWD-2, TWD, and AIN-93G will be 
carried out. Through this study, we expect to better understand how the whole-food component of 
the TWD-2 affects colorectal carcinogenesis in response to AOM + DSS induced inflammation.  
We also hope this study will directly influence a change within the scientific research community 
by demonstrating the importance of incorporating whole-foods into rodent diets used in studies 
pertaining to colon health. Incorporating the TWD-2 into dietary studies will likely make the 
rodent a better human model, potentially allowing researchers to better understand the etiology of 
CRC. 
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